JP2002542179A - Skin care compositions containing combinations of skin care actives - Google Patents

Abstract

  (57) [Summary] The present invention relates to skin care compositions containing a combination of skin care actives and methods of using the compositions to condition the skin. The composition comprises a safe and effective amount of farnesol; a safe and effective amount of bisabolol; a safe and effective amount of at least one additional skin care active; and a dermatologically acceptable carrier. I do.

Description

DETAILED DESCRIPTION OF THE INVENTION

FIELD OF THE INVENTION [0001] The present invention relates to a topical composition containing a skin care active, in particular farnesol, bisabolol, and at least one additional skin care active. Such compositions are effective in regulating the condition of the skin, in particular in regulating visible and / or tactile discontinuities associated with the skin, for example skin aging. Preferred compositions further contain phytantriol.

BACKGROUND OF THE INVENTION [0002] Many personal care products currently available to consumers are primarily directed at improving skin health and / or physical appearance. Many of these skin care products are directed to delaying, minimizing or even eliminating skin wrinkles and other histological changes typically associated with skin aging or environmental damage to human skin. ing. A number of compounds have been identified in the art as being effective in modulating skin condition, including adjusting fine lines, wrinkles, and other uneven or rough surface textures associated with aging or light-induced skin damage. In detail.

[0003] Skin is exposed to attacks by a number of extrinsic and intrinsic factors. Extrinsic factors include ultraviolet light (eg, due to sunlight exposure), environmental pollution, wind, heat, low humidity, harsh surfactants, abrasives, and the like. Endogenous factors include aging and other biochemical changes inside the skin. These factors, whether extrinsic or intrinsic, are indicative of skin aging and other visible signs of environmental damage, such as wrinkles and other forms of roughness (pore size, flakes, and skin And other histological changes associated with aging or damage to the skin. For many people, skin wrinkles are reminiscent of the loss of youth. As a result, wrinkle removal has become a rapidly developing business in a youth-conscious society. Processing ranges from cosmetic creams and moisturizers to various forms of cosmetic surgery.

[0004] Extrinsic or intrinsic factors can cause skin thinning and overall deterioration. For example, as the skin ages naturally, the cells and blood vessels that supply the skin decrease. The dermal-epidermal junction also flattens, and as a result, the mechanical resistance at this junction is further reduced. See, for example, Oikarinen, "Aging of the skin: Aging against photoaging (" The Ag "), all of which are incorporated herein by reference.
ing of Skin: Chronoaging Versus Photoaging ")", Photodermatol. Photoimm
See unol. Photomed., 7, 3-4, 1990.

[0005] A number of skin care actives are known in the art and are used to improve skin health and / or skin appearance. For example, salicylic acid and benzoyl peroxide are used in skin care compositions to treat acne. Retinoids are another example of skin care actives used in skin care compositions to reduce the signs of skin aging. Although the incorporation of such actives in skin care compositions has skin care benefits, the incorporation of such compositions poses additional challenges.
For example, retinoid compositions typically must be prepared under special conditions, such as in an inert atmosphere, and sometimes do not exhibit optimal stability, such as discoloration. Compositions containing certain skin care actives may cause tingling, burning,
May cause skin irritation such as redness.

[0006] Based on the foregoing, improve skin health and / or skin appearance, for example, aesthetically pleasing, stable, and wrinkles, fine lines, holes, poor skin color There is a continuing need to formulate skin care compositions that are effective in treating appearances such as (eg, redness, earth color, and other forms of unwanted skin surface texture).

Surprisingly, compositions containing a number of active systems, in particular farnesol, in combination with bisabolol and at least one additional skin care active are known to the inventors of the present invention in the preparation of skin conditions. Provides effects not previously recognized in the art. For example, topical application of farnesol in combination with bisabolol and at least one additional skin care active will produce fine lines, wrinkles,
Reduce (prophylactically and / or therapeutically) visible and / or palpable mammalian skin discontinuities, including enlarged pores, roughness, dryness, and other skin texture discontinuities Can be adjusted synergistically, for example, to obscure or eliminate fine lines, wrinkles, and other forms of bumpy or rough surface texture that occur in aged or light damaged skin . No technology offers all the advantages and benefits of the present invention.

SUMMARY OF THE INVENTION The present invention provides a safe and effective amount of farnesol; a safe and effective amount of bisabolol; a safe and effective amount of at least one additional skin care active;
And a dermatologically acceptable carrier. The invention further relates to a method of using such compositions to regulate the condition of mammalian skin. The method comprises topically applying the composition, usually to a mammalian skin in need of such treatment, with a safe and effective amount of such composition. I do. A preferred embodiment includes phytantriol. These and other features, aspects, and advantages of the present invention will be apparent to those skilled in the art from a reading of the present specification.

DETAILED DESCRIPTION OF THE INVENTION While this specification concludes with claims particularly pointing out and distinctly claiming the invention, the invention will be better understood from the following description. it is conceivable that. All percentages and ratios used herein are by weight of the total composition and, unless otherwise indicated, all measurements are made at 25 ° C. The compositions of the present invention may comprise, consist essentially of, or consist of the components of the present invention, as well as other components described herein. As used herein, "consisting essentially of" means that the composition or the components may comprise additional components, in which case the additional components are the basis of the claimed composition or method. Meaning that the new and novel features are not substantially changed. All publications cited herein are incorporated herein by reference.

[0010] As used herein, the term "keratinous tissue" refers to a mammal (eg, including, but not limited to, skin, lips, hair, toenails, fingernails, epidermis, hooves, etc.) Keratin-containing layer disposed as the outermost protective coating of humans, dogs, cats, etc.). As used herein, the term "topical application" refers to the application or application of a composition of the present invention to the surface of keratinous tissue. As used herein, the term "dermatologically acceptable" refers to those compositions or components so described that are unduly toxic, incompatible, unstable,
It means that it is suitable to be used in contact with keratin tissue of a mammal without having an allergic reaction or the like. As used herein, the term "safe and effective amount" refers to a significant elicited benefit, preferably a pronounced keratinous tissue appearance or feel benefit, within the sound judgment of the skilled artisan. Is sufficient to significantly induce, and includes, independently or in combination, those benefits disclosed herein, but low enough to avoid serious side effects, i.e., a reasonable benefit versus risk Means the amount of the compound or composition that provides the ratio. As used herein, the term "slacking" refers to the disappearance, damage,
Means a condition of the skin such as relaxation, loosening, etc. resulting from changes and / or abnormalities. As used herein, the terms "smooth" and "soften" refer to altering the surface of keratinous tissue to improve its feel.

“Symptoms of skin aging” include any deterioration due to externally visible and tactilely perceptible skin aging, as well as any other macro- or micro-effects. Not limited. Such signs may be induced or caused by intrinsic or extrinsic factors, such as aging and / or environmental damage. These signs include, but are not limited to, normal wrinkles and coarse and deep wrinkles, skin lines, cracks, bruises, large holes (eg, appendages such as sweat glands, sebaceous glands or hair follicles) Structure-related) or the occurrence of structural discontinuities such as skin unevenness or roughness, loss of skin elasticity (loss and / or inactivation of functional skin elastin), sagging (eye area or Jaw swelling), loss of skin firmness, loss of skin tone, loss of skin deformity, discoloration (including under the eyes), spots, paleness, hyperpigmentation such as age spots and freckles Skin area, keratosis, abnormal differentiation,
Hyperkeratinization, elastic fibrosis, collagen degradation, stratum corneum, dermis, epidermis, dermal vasculature (eg, telangiectasia or spider vasculature), and other underlying tissues, especially those proximal to the skin Can result from processes involving histological changes.

The present invention is useful for therapeutically adjusting visible and / or palpable discontinuities in mammalian skin, including skin texture and color discontinuities. For example, the apparent pore diameter decreases and shortens, the apparent height of the tissue closest to the aperture opening approaches the height of the skin tissue in the appendage, and the skin tone / color becomes uniform. And / or reduced length, depth, and / or other line and / or wrinkle dimensions.

[0013] The compositions of the present invention are effective for regulating the condition of the skin and in particular for regulating the condition of keratinous tissue. Modulation of the skin condition, i.e., the skin condition of mammals and especially humans, is often necessary due to conditions that may be induced or attributed to intrinsic and / or extrinsic factors of the body. Examples include environmental damage, exposure to radiation (including ultraviolet light), aging, menopause (eg, changes in skin after menopause), stress, illness, and the like. For example, "modulating skin condition" includes prophylactic and / or therapeutic adjustment of skin condition, and includes one or more of the following advantages: skin conditioning to reduce skin atrophy. Thickening (ie, formation of epidermal and / or dermal and / or subcutaneous (eg, subcutaneous fat or muscle) layers of the skin where the keratin layers of the nail and hair shaft are appropriate), increased convolution at the boundary between the dermis and epidermis Loss of skin elasticity (also known as interpapillary embolism), loss of skin elasticity such as elastic fibrosis (loss of functional skin elastin, damage and / or inactivation), loss of skin elasticity due to loosening and deformation Prevention; non-melaninous skin discoloration, such as dark circles under the eyes, spots (eg, uneven red coloration due to rosacea) (hereinafter referred to as "red spots"), poor reddish color (pale white) ), In telangiectasia or spider vessels It includes prevention of discoloration.

As used herein, prophylactic skin condition regulation includes visible and / or tactile skin discontinuities (eg, visible or tactile detectable). Slowing, minimizing, and / or preventing skin texture irregularities). As used herein, therapeutic adjustment of skin condition includes improving, eg, reducing, minimizing, and / or eliminating skin irregularities. The compositions of the present invention are further effective in improving skin appearance and / or hand. For example, the compositions of the present invention are effective in adjusting the appearance of skin conditions,
Provides a rapid visual improvement in skin appearance after application of the composition to the skin. Generally, particulate compositions are most effective to provide rapid visual improvement.

The compositions of the present invention provide additional benefits, including their stability, lack of significant (unacceptable to the consumer) skin irritation, and aesthetics. The composition of the present invention is stable. The components used in the present invention, including farnesol, bisabolol, and other skin care actives, are stable in the composition and compatible with each other. Thus, the composition containing the combination of farnesol, bisabolol, and at least one additional skin care active can provide an additive effect and / or a synergistic skin effect. Moreover, the resulting skin care composition has good product stability and a fairly long shelf life.

[0016] Compositions containing the combination of farnesol, bisabolol, and at least one additional skin care active result in an aesthetic appearance. Examples of aesthetically pleasing are: (i) light and non-greasy, (ii) a smooth, smooth feel on the skin, (iii) easily stretched and / or (iv) quickly absorb, comfortable And compositions such as fresh creams and lotions. Other examples of aesthetics include compositions that provide a consumer-acceptable appearance (ie, no unpleasant scent or discoloration) and a good skin feel. The composition of the present invention contains farnesol, bisabolol, and at least one additional skin care active, and a dermatologically acceptable carrier. The compositions of the present invention may further comprise a wide variety of other optional ingredients. The details of the composition of the present invention are described below.

I. Farnesol The topical composition of the present invention contains a safe and effective amount of farnesol. Farnesol is a natural substance that is thought to act as a precursor and / or intermediate in the biosynthesis of squalene and sterols, especially cholesterol. Farnesol also has a nuclear receptor that is involved in protein modification (eg, farnesylation of proteins) and is responsive to farnesol. Farnesol is chemically [2E, 6E] -3,7,11-trimethyl-2,6,10-dodecatrien-1-ol, and as used in the present invention, "farnesol" includes: It includes its isomers and tautomers. Farnesol, for example, under the trade name Farnesol as a mixture of isomers
Dragoco, 10 Gordon Drive, Totowa, New Jersey) and under the trade name Trans-Trans-Farnesol (Sigma chemical Compa)
ny, PO Box 14508, St. Louis, Missouri). The compositions of the present invention preferably comprise from about 0.001 to about 50%, more preferably from about 0.01 to about 20%, even more preferably from about 0.1 to about 15%, by weight of the composition. And even more preferably about 0.1 to about 10% by weight, even more preferably about 0.5 to about 5% by weight, even more preferably about 1 to about 5% by weight of farnesol.

II. Bisabolol The topical compositions of the present invention contain a safe and effective amount of bisabolol. Bisabolol is a natural unsaturated monocyclic terpene alcohol having the following structure.

Embedded image

Bisabolol is the main active component of the chamomile extract / chamomile oil component. Bisabolol can be synthesized (d, l-α-isomer or (+/−)-α-
Isomer) or natural ((-)-α-isomer).
It can be used as an essentially pure compound or a mixture of compounds (eg, an extract from a natural source such as chamomile). Α of bisabolol (a-bisabolol)
The body is used in various cosmetic products as a skin conditioning or soothing agent. As used herein, "bisabolol" includes chamomile extract or chamomile oil and any isomers and tautomers thereof. Suitable bisabolol compounds are commercially available from Dragoco (Totowa, NJ) as the natural product under the product name Natural α-Bisabolol and synthetic products under the product name α-Bisabolol from Fluka (Fluka, Milwaukee, WI). The compositions of the present invention preferably comprise from about 0.001 to about 50%, more preferably from about 0.01 to about 20%, even more preferably from about 0.01 to about 15%, by weight of the composition, and Even more preferably, it contains about 0.1 to about 10% by weight, even more preferably about 0.1 to about 5% by weight bisabolol.

III. Additional Skin Care Actives The compositions of the present invention contain at least one additional skin care active.
The compositions of the present invention may furthermore contain additional skin care actives.

In a preferred embodiment, if the composition is to be in contact with human keratinous tissue, the additional skin care active (s) should be suitable for application to keratinous tissue That is, when mixed into the composition,
They are suitable for use in contact with human keratinous tissue within the scope of sound medical judgment, without showing undue toxicity, incompatibility, instability, allergic reactions and the like. CTFA Cosmetic Ingredient Handbook (
CTFA Cosmetic Ingredient Handbook), Second Edition (1992), describes various non-limiting cosmetic and pharmaceutical components commonly used in the industry related to skin care, which are the compositions of the present invention. Suitable for use on objects. Examples of such ingredients are: cosmetic ingredients such as abrasives, absorbents, perfumes, pigments, colorants / colorants, essential oils, skin irritants, astringents (eg clove oil, menthol, camphor) , Eucalyptus oil, eugenol, menthyl lactate, witch hazel distillate), anti-acne agents, anti-solidification agents, defoamers, antibacterial agents (eg, iodopropyl butyl garbamate), antioxidants, binders, biology Additives, buffers, fillers, chelating agents, chemical additives, coloring agents, cosmetic astringents, cosmetic biocides, denaturants,
Medicinal astringents, topical analgesics, film-forming agents or substances, such as polymers (eg, copolymers of eicosene and vinylpyrrolidone), which aid film-forming and direct-dyeing properties of the composition, opacifiers, pH adjusters, jetting Agents, reducing agents, sequestrants, skin bleaching and whitening agents (eg, hydroquinone, kojic acid, ascorbic acid, magnesium ascorbyl phosphate, ascorbyl glucosamine), skin conditioning agents (including other and occlusive) Moisturizers), skin smoothing and / or therapeutic agents (eg, panthenol and derivatives (eg, ethyl panthenol)),
Aloe vera, pantothenic acid and its derivatives, allantoin, bisabolol and dipotassium glycyrrhizinate), skin treatments, thickeners and vitamins and their derivatives.

However, in any of the embodiments of the present invention, the active agents useful herein can be categorized according to the benefits they provide or their mode of action assumed. It should be understood, however, that the actives useful herein may in some cases provide multiple effects or work through multiple modes of action. Therefore, the classification herein is for convenience only and is not intended to limit activity to any particular application or listed application.

Phytantriol The topical composition of the present invention may contain a safe and effective amount of phytantriol. Phytantriol is the common name for a chemical known as 3,7,11,15-tetramethylhexadecane-1,2,3-triol. Phytantriol is commercially available from BASF (1609 Biddle Avenue, Whyandotte, MI). For example, phytantriol is used as a spider-like blood vessel / red rash repair agent,
Swelling eye repair agent, pale complexion repair agent, loosening repair agent, anti-itch agent, skin thickener,
It is effective as a pore-reducing agent, oil / gazing relieving agent, post-inflammatory pigmentation repairing agent, wound healing agent, and anti-cellulite agent for regulating skin texture, including wrinkles and fine lines. When included in the compositions of the present invention, phytantriol is preferably present at about 0.001% to about 50%, more preferably about 0.01% to about 20%, even more preferably about 0.1% by weight of the composition. 1 to about 15% by weight, even more preferably about 0.2 to about 10
%, More preferably from about 0.5 to about 10%, and even more preferably from about 1 to about 5% by weight.

Exfoliating Actives A safe and effective amount of exfoliating actives can be added to the compositions of the present invention, more preferably from about 0.1 to about 10% by weight of the composition, even more preferably. May add from about 0.2 to about 5% by weight, more preferably from about 0.5 to about 4% by weight. Exfoliating actives enhance the effect on the appearance of the skin of the present invention. For example, exfoliating actives tend to improve the texture (eg, smoothness) of the skin. One suitable release system for use in the present invention contains a sulfhydryl compound and a zwitterionic surfactant, which is described in U.S. Patent No. 5,681,852 (Bissett) and is incorporated by reference. It is incorporated by reference herein. Another release system suitable for use in the present invention comprises salicylic acid and a zwitterionic surfactant,
No. 5,652,228 (Bissett),
It is cited and incorporated herein by reference. Zwitterionic surfactants such as those described in these applications are also useful as release agents herein, with cetylbetaine being particularly preferred.

Anti-Acne Actives The compositions of the present invention may contain a safe and effective amount of one or more anti-acne actives. Examples of effective anti-acne actives include resorcinol, sulfur, salicylic acid, benzoyl peroxide, erythromycin, zinc and the like.
For further examples of suitable anti-acne actives, see US Pat. No. 5,607,980.
No. (McAtee et al., Issued March 4, 1997).

Anti-wrinkle actives / anti-atrophy actives The compositions of the present invention may further comprise a safe and effective amount of one or more anti-wrinkle or anti-atrophy actives. Representative anti-wrinkle actives / anti-atrophy actives suitable for use in the compositions of the present invention include sulfur-containing D and L amino acids and their derivatives and salts, especially N-acetyl derivatives, Preferred examples are N-acetyl-L-cysteine; thiols such as ethanethiol; hydroxy acids such as α-hydroxy acids such as lactic acid and glycolic acid, or β-hydroxy acids such as salicylic acid, and octanoyl derivatives. Salicylic acid derivatives), phytic acid, lipoic acid; lysophosphatidic acid, skin exfoliants (eg, phenol, etc.), the effects of the present invention on the appearance of keratinous tissue, especially in the regulation of keratinous tissue condition, eg skin condition vitamin B ₃ compounds enhance the effect and contains retinoids.

A) Vitamin B ₃ Compound The composition of the present invention may contain a safe and effective amount of a vitamin B ₃ compound.
Vitamin B ₃ compounds are copending application, Serial No. 08 / 834,010 (1
It is particularly useful for regulating the condition of the skin, as described in WO 97/39733 A1, published October 30, 997). When there are vitamin B ₃ compound in the compositions of the present invention, the composition, preferably from about 0.01 to about 50% by weight of the composition, more preferably from about 0.1 to about 10 wt%, even more preferably from about 0.5 to about 10 wt%, and even more preferably from about 1 to about wt 5%, even more preferably from about 2 to about 5 wt% of the vitamin B ₃ compound.

As used herein, “vitamin B ₃ compound” means a compound having the following structural formula:

Embedded image Wherein, R -CONH ₂ (i.e., nicotinic acid amide), - COOH (i.e., nicotinic acid) or -CH ₂ OH (i.e., nicotinyl alcohol); is and salts of any of the above; their derivatives . Exemplary derivatives of the foregoing vitamin B ₃ compounds, non-vasodilating esters of nicotinic acid (e.g., tocopheryl nicotinate), nicotinyl amino acids, nicotinyl alcohol esters of carboxylic acids, nicotinic acid N- oxide and nicotine Nicotinic acid esters are included, including acid amide N-oxides. Examples of suitable vitamin B ₃ compounds are well known in the art, they are a number of sources, e.g., Sigma Chemical Company (Sigma Chemical Company) (
St. Louis, Mo .; ICN Biomedicals, Inc.
. (Irvine, Calif.) And Aldrich Chemical Company (Milwaukee, Wis.). The vitamin compound may be included as a substantially pure material or as an extract obtained by suitable physical and / or chemical separation from natural (eg, plant) sources.

B) Retinoid The composition of the present invention may further contain a retinoid. As used herein, “retinoid” is a vitamin A that has the biological activity of vitamin A in the skin
Or all natural and / or synthetic analogs of retinol-like compounds, as well as geometric and stereoisomers of these compounds. The retinoid is preferably retinol, retinol esters (e.g., retinyl palmitate, retinyl acetate, C ₂ -C ₂₂ alkyl esters of retinol, including retinyl propionate), retinal, and / or retinoic acid (and all-trans retinoic acid And / or 13-cis-retinoic acid), and more preferably a retinoid other than retinoic acid. These compounds are well known in the art and are available from a number of sources such as, for example, the Sigma Chemical Company (St. Louis, Mo., USA) and Boehringer Mannheim (Indianapolis, Indiana, USA). More commercially available. Other retinoids useful herein are U.S. Patent No. 4,677,120 (Palish et al., Issued June 30, 1987); U.S. Patent No. 4,885,3.
No. 11 (Parrish et al., Issued December 5, 1989); US Pat. No. 5,049,
No. 584 (Paris et al., Issued Sep. 17, 1991); US Pat. No. 5,124.
No. 356 (Paris et al., Issued Jan. 23, 1992); and U.S. Pat. No. 34,075 (Paris et al., Issued Sep. 22, 1992). Other suitable retinoids are tocopheryl-retinoate [retinoic acid (
Trans- or cis-) tocopherol ester, adapalene {6- [3- (
1-adamantyl) -4-methoxyphenyl] -2-naphthoic acid} and tazarotene (ethyl 6- [2- (4,4-dimethylthiochroman-6-yl) -ethynyl] nicotinic acid ester). Preferred retinoids are retinol, retinyl palmitate, retinyl acetate, retinyl propionate, retinal and salts thereof.

The retinoid may be included as a substantially pure substance or as an extract obtained by suitable physical and / or chemical isolation from natural (eg, plant) resources. The retinoid is preferably substantially pure, more preferably essentially pure.

The composition of the present invention is characterized in that the resulting composition modulates the condition of the keratinous tissue, preferably the discontinuity of the visible and / or palpable skin structure, more preferably the skin aging Adjustment of the signs of, more preferably associated with skin aging,
It may include a safe and effective amount of a retinoid for adjustment of visible and / or palpable skin texture discontinuities. The composition preferably comprises from about 0.005% to about 2%,
More preferably, it contains 0.01% to about 2% retinoids. Retinol is preferably used in an amount from about 0.01% to about 0.15%;
Preferably used in an amount of about 0.01% to about 2% (eg about 1%); retinoic acid is preferably used in an amount of about 0.01% to about 0.25%; tocopheryl retinoate , Adapalene, and tazarotene are preferably used in an amount of about 0.01% to about 2%.

When the composition of the present invention contains both a retinoid and a vitamin B ₃ compound,
Its retinoid is preferably used in an amount of above, and the vitamin B ₃ compound is preferably from about 0.1% to about 10%, is more preferably used in an amount of about 2% to about 5%.

(C) Hydroxy Acid The composition of the present invention may contain a safe and effective amount of a hydroxy acid. Preferred hydroxy acids for use in the compositions of the present invention include salicylic acid and salicylic acid derivatives. Salicylic acid, when present in the compositions of the present invention, preferably comprises
. 01 to about 50%, more preferably about 0.1 to about 20%, even more preferably about 0.1 to about 10%, even more preferably about 0.5 to about 5%, and even more preferably about Used in amounts from 0.5 to about 2%.

Peptides The compositions of the present invention include a safe and effective amount of an additional peptide, including but not limited to di-, tri-, tetra-, and pentapeptides and derivatives thereof. obtain. As used herein, "peptide" refers to both natural and synthetic peptides. Also useful herein are natural and commercial compositions containing the peptide.

Suitable dipeptides for use in the present invention include carnosine (β-Ala-His)
Is included. Tripeptides suitable for use in the present invention include Gly-His-Ly
s, Arg-Lys-Arg, His-Gly-Gly. Preferred tripeptides and their derivatives include Biopeptide CL (Biopeptide CL) (
Palmitoyl-Gly-His-Lys which may be marketed under the trademark
(100 ppm palmitoyl commercially available from Sederma, France)
Gly-His-Lys); Peptide CK (Arg-Lys-Arg); Peptide CK + (ac-Arg-Lys-Arg-NH ₂ ); His-G
ly-Gly copper derivatives are included. Tetrapeptides suitable for use in the present invention include peptide E, Arg-Ser-Arg-Lys (SEQ ID NO: 1). Pentapeptides suitable for use in the present invention include Lys-Thr-Thr-Lys
-Ser is included. A preferred composition containing a commercially available pentapeptide derivative is Matrixyl®, 100 ppm of palmitoyl-
Contains Lys-Thr-Thr-Lys-Ser (SEQ ID NO: 2) and is commercially available from Sederma, France.

Preferably, the additional peptide is palmitoyl-Lys-Thr-Thr-L
ys-Ser, palmitoyl-Gly-His-Lys, β-Ala-His,
Selected from their derivatives, and combinations thereof. More preferably, the peptide is selected from palmitoyl-Lys-Thr-Thr-Lys-Ser, palmitoyl-Gly-His-Lys, derivatives thereof, and combinations thereof. Even more preferably, the peptide is palmitoyl-Lys-Thr
Selected from -Thr-Lys-Ser, their derivatives, and combinations thereof.

When used in the compositions of the present invention, the peptide preferably comprises about 1 × 10 ^-6 To about 10% by mass, more preferably about 1 × 10^-6To about 0.1% by mass, even more preferable
Preferably about 1 × 10^-FiveAmounts of from about 0.01% by weight. The peptide is cal
For compositions that are Carnosine®, preferably about 0.5% of the composition.
It contains 1 to about 5% by weight of the peptide. Peptide-containing composition, Matrixil
(Matrixyl) (registered trademark) and / or Biopeptide CL (Biopeptide CL) (
In other embodiments, including (registered trademark), the composition is preferably from about 0.01 to about 10
Wt% Matrixyl® and / or biopeptide CL
(Biopeptide CL) (registered trademark).

Antioxidant / Radical Scavenger The compositions of the present invention may include a safe and effective amount of an antioxidant / radical scavenger. Antioxidants / radical scavengers are particularly useful for protecting against UV irradiation, which increases scaly detachment or tissue changes in the stratum corneum, and other environmental chemicals that can cause skin damage. A safe and effective amount of an antioxidant / radical scavenger is added to the composition of the present invention at a concentration of preferably from about 0.1 to about 10%, more preferably from about 1 to about 5% by weight of the composition. Can be added.

Ascorbic acid (vitamin C) and its salts, ascorbic acid esters of fatty acids, ascorbic acid derivatives (eg, magnesium ascorbate phosphate, sodium ascorbate phosphate, ascorbate sorbate), tocopherol (vitamin E), sorbic acid Tocopherol, tocopherol acetate, other tocopherol esters, butylated hydroxybenzoic acid and salts thereof, 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (trade name: Trolox (registered trademark) Commercially available as a trademark)), gallic acid and its alkyl esters, especially propyl gallic acid, uric acid and its salts and alkyl esters,
Sorbic acid and its salts, lipoic acid, amines (e.g., N, N-diethylhydroxylamine, amino-guanidine), sulfhydryl compounds (e.g., glutathione), dihydroxyfumaric acid and its salts, lysipidrate, arginine pyrrolate, nor Dihydroguaiaretic acid, bioflavonoids, curcumin, lysine,
Antioxidants / radical scavengers may be used, such as methionine, proline, superoxide dismutase, silymarin, tea extract, grape skin / seed extract, melanin, and rosemary extract. Preferred antioxidants / radical scavengers are selected from tocopherol sorbate and other esters of tocopherol, more preferably tocopherol sorbate. For the use of tocopherol sorbate in topical compositions and those applicable to the present invention, see Donald L. Bissett, Rodney Bush.
ney D. Bush) and Ranjit chatterjee (198)
No. 4,847,071 issued Jul. 11, 1997.

Chelating Agents The compositions of the present invention may further contain a safe and effective amount of a chelator or chelating agent. As used herein, the term "chelator" or "chelating agent" means that a metal ion does not easily participate in a chemical reaction or catalyze a chemical reaction.
An active substance capable of removing a metal ion from a system by forming a complex. The inclusion of a chelating agent is particularly useful for protecting against ultraviolet radiation that contributes to scaling or tissue changes in the stratum corneum and from other environmental chemicals that can cause skin damage. is there.

A safe and effective amount of a chelating agent may be added to the composition of the subject invention, preferably from about 0.1% to about 10%, more preferably from about 1% to about 5% of the composition. Is also good. Representative chelating agents useful herein are U.S. Patent No. 5,487,884 (Bissett et al., Issued January 30, 1996); WO 91/16035 (Bush). (Bush) et al., Published October 30, 1995); and WO 91/16034 (Bush et al., Published October 31, 1995). Preferred chelating agents useful in the compositions of the present invention are furildioxime, furilmonooxime, and derivatives thereof.

Flavonoids The compositions of the present invention may optionally contain a flavonoid compound. Flavonoids are widely disclosed in U.S. Patent Nos. 5,686,082 and 5,686,367, both of which are incorporated herein by reference. Flavonoids suitable for use in the present invention are flavanones selected from unsubstituted flavanones, monosubstituted flavanones, and mixtures thereof; unsubstituted chalcone, monosubstituted chalcone, disubstituted chalcone, trisubstituted chalcone, and mixtures thereof. Selected chalcones; unsubstituted flavone, monosubstituted flavone, disubstituted flavone, and flavone selected from mixtures thereof; one or more isoflavones; unsubstituted coumarin, monosubstituted coumarin, disubstituted coumarin, and the like A coumarin selected from a mixture of: chromones selected from unsubstituted chromones, monosubstituted chromones, disubstituted chromones, and mixtures thereof; one or more dicoumarols; one or more chromanones; one Or more chromanols; their isomers (
And cis / trans isomers); and mixtures thereof. As used herein, the term "substituted" means that one or more hydrogen atoms are independently
Hydroxyl, C1-C8 alkyl, C1-C4 alkoxyl, O-glycoside, etc., or a flavonoid substituted by a mixture of these substituents.

Examples of suitable flavonoids include unsubstituted flavanones, mono-hydroxyflavanones (eg, 2′-hydroxyflavanone, 6-hydroxyflavanone, 7-hydroxyflavanone, etc.), mono-alkoxyflavanones (eg, 5-methoxyflavanone) Flavanone, 6-methoxyflavanone, 7-methoxyflavanone, 4′-methoxyflavanone, etc., unsubstituted chalcone (particularly unsubstituted trans-chalcone), mono-
Hydroxychalcone (eg, 2′-hydroxychalcone, 4′-hydroxychalcone, etc.), di-hydroxychalcone (eg, 2 ′, 4-dihydroxychalcone, 2 ′, 4′-dihydroxychalcone, 2,2′-dihydroxychalcone) , 2 ', 3
-Dihydroxychalcone, 2 ', 5'-dihydroxychalcone, etc.) and tri-hydroxychalcone (e.g., 2', 3 ', 4'-trihydroxychalcone, 4,2',
4′-trihydroxychalcone, 2,2 ′, 4′-trihydroxychalcone, etc.),
Unsubstituted flavone, 7,2'-dihydroxyflavone, 3 ', 4'-dihydroxynaphthoflavone, 4'-hydroxyflavone, 5,6-benzoflavone and 7,8
-Benzoflavone, unsubstituted isoflavone, daidozyne (7,4'-dihydroxyisoflavone), 5,7-dihydroxy-4'-methoxyisoflavone, soy isoflavone (mixture extracted from soy), unsubstituted coumarin, 4-hydroxycoumarin, 7-hydroxycoumarin, 6-hydroxy-4-methylcoumarin, unsubstituted chromone, 3-formylchromone, 3-formyl-6-isopropylchromone, unsubstituted dicoumarol, unsubstituted chromanone, unsubstituted chromanol and mixtures thereof. However, it is not limited to these.

Preferred for use in the present invention are unsubstituted flavanones, methoxyflavanones, unsubstituted chalcone, 2 ', 4-dihydroxychalcone and mixtures thereof. Even more preferred are unsubstituted flavanones, unsubstituted chalcone (especially trans isomers), and mixtures thereof.

These can be synthetic or obtained as extracts from natural resources (eg plants). It is also possible to derive substances that are supplied in nature (eg, ester or ether derivatives produced after extraction from natural resources). Flavonoid compounds useful in the present invention can be obtained from a number of sources, including, for example, Indofine Chemical Company, Inc. (Summerville, NJ, USA), Stellaloids, Inc. (Wilton, NH, USA) ) And Aldrich Chemical Company, Inc. (Milwaukee, WI, USA).

A mixture of the above flavonoid compounds may be used. The flavonoid compounds described herein are preferably present in the present invention at about 0.01
To about 20%, more preferably about 0.1 to about 10%, and even more preferably about 0 to about 20%.
. It is present at a concentration of 5 to about 5%.

Anti-Inflammatory Agent A safe and effective amount of an anti-inflammatory agent in the composition of the present invention is preferably administered in an amount of about
. It can be added at a concentration of 1 to about 10%, more preferably about 0.5 to about 5%. Anti-inflammatory agents enhance the effect on skin appearance in the present invention, for example, such agents contribute to a more uniform and desirable skin tone or color. Because such agents are broadly effective, the exact amount of anti-inflammatory agent used in the composition will depend on the particular anti-inflammatory agent utilized.

[0048] Steroidal anti-inflammatory agents that may be used include hydrocortisone, hydroxyltriamcinolone, alpha-methyldexamethasone, dexamethasone-phosphate, beclomethasone dipropionate, clobetasol valerate, desonide,
Desoxymethasone, desoxycorticosterone acetate, dexamethasone, dichlorisone, diflorasone diacetate, diflucorthorone valerate, fluadrenolone, fluchlorolone acetonide, fludrocortisone, flumethasone pivalate, fluocinolone acetonide, fluocinonide, Flucortin butyl ester, fluocortron, fluprednidene (fluprednylidene) acetate, flulandrenolone, halcionide, hydrocortisone acetate, hydrocortisone butyrate, methylprednisolone, triamcinolone acetonide, cortisone, cortodoxone, flucetonide, fludrocortisone, dizide Difluorosone acetate, fluradolenolone, fludrocortisone, difluroson diacetate, fluradolenolone acetonide, Dorizon, amcinafel, amcinafide, betamethasone and its esters, chloro prednisone, acetic chloro prednisone, clocortelone, Kureshinoron, dichlorisone, difluprednate de sulfonates, Fururoronido,
Corticosteroids such as flunisolide, fluoromesalone, fluperolone, fluprenisolone, hydrocortisone valerate, hydrocortisone cyclopentylpropionate, hydrocortamate, meprednisolone, paramethasone, prednisolone, prednisone, beclomethasone dipropionate, triamcinolone and the like , But is not limited to. A preferred steroidal anti-inflammatory is hydrocortisone.

[0049] A second class of anti-inflammatory agents useful in the above compositions is non-steroidal anti-inflammatory agents.
Within this group are various compounds known to those skilled in the art. Details of the chemical structure, synthesis, side effects, etc. of non-steroidal anti-inflammatory agents are described in D. Rainsfold (KD
Rainsford) "Anti-inflammatory and anti-rheumatic drugs (anti-inflammatory and anti-rheumatic drugs)" I
-Volume III, CRC Press, Boca Raton (19)
1985); A. RA Scherrer et al., "Anti-inflammatory Agents, Chemistry and Pharmacology", Volume 1,
Standard textbooks can be referenced, including Academic Press, New York (1974).

Specific non-steroidal anti-inflammatory agents useful in the compositions of the present invention include: 1) piroxicam, isoxicam, tenoxicam, sudoxicam, and CP-
Oxicams such as 14,304; 2) salicylates such as aspirin, disalside, benolylate, trisate, safapurine, sorbulin, diflunisal, and fendosal; 3) diclofenac, fenclofenac, indomethacin, sulindac, tolmetin, isoxepak, flofenac Acetic acid derivatives such as thiopinac, zidomethacin, acematacin, fenthiazac, zomepirac, clindanac, oxepinac, felbinac, and ketorolac; 4) fenamic acids such as mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid, and tolfenamic acid; Ibuprofen, naproxen, benoxaprofen, flurbiprofen, ketoprofen, fenoprofen, fenbufen, indoprofen,
Propionic acid derivatives such as pirprofen, carprofen, oxaprofin, pranoprofen, miloprofen, thiooxaprofen, suprofen, aluminoprofen, and thioprofen; and 6) phenylbutazone, oxyfenobtazone, feprazone, azaproprazone, and trimetasone But not limited thereto.

Mixtures of such non-steroidal anti-inflammatory agents may be used, as well as dermatologically acceptable salts and esters of such drugs. For example, etofenamate, a derivative of flufenamic acid, is particularly useful for topical application. Of the non-steroidal anti-inflammatory agents, ibuprofen, naproxen, flufenamic acid, etofenamate, aspirin, mefenamic acid, meclofenamic acid, piroxicam, and felbinac are preferred; ibuprofen, naproxen, ketoprofen, etofenamate, aspirin and flufenamic acid are preferred More preferred.

Finally, so-called “natural” anti-inflammatory agents are effective in the method of the present invention. Such anti-inflammatory agents are suitably obtained from natural resources (eg, by-products of plants, fungi, microorganisms) as extracts by suitable physical and / or chemical isolation, or can be obtained synthetically. . For example, candelia wax, bisabolol (for example, α
-Bisabolol), aloe vera, plant sterols (eg phytosterols), Manjistha (Rubiaceae plants, especially Rubia)
Cordifolia (extracted from Rubia Cordifolia)) and Guggal (
Commiphora plants, especially from Commiphora Mukul (extracted from Commiphora Mukul), kola extract, chamomile, purple clover extract, and coral extract can be used.

Further useful anti-inflammatory agents herein include liquorice [Glycyrrhiza glabra], including glycyrrhetinic acid, glycyrrhizic acid, and derivatives (eg, salts and esters) thereof. ] Family compounds. Suitable salts of the compounds include metal and ammonium salts. Suitable esters, C ₂ -C ₂₄ saturated or unsaturated esters of the acids, preferably C _{1 0} -C _24, more preferably include C ₁₆ -C _24. Examples of the above include oil-soluble liquorice extract, glycyrrhizic acid and glycyrrhetinic acid itself, monoammonium glycyrrhizinate, monopotassium glycyrrhizinate, dipotassium glycyrrhizinate, 1-β-glycyrrhetinic acid, stearyl glycyrrhetinate, and 3-
Stearyl-glycyrrhetinic acid and disodium 3-succinyloxy-β-glycyrrhetinate are included. Stearyl glycyrrhetinate is preferred.

Anti-cellulite agents The compositions of the present invention may further comprise a safe and effective amount of an anti-cellulite agent.
Suitable agents can include, but are not limited to, xanthine compounds (eg, caffeine, theophylline, theobromine, and aminophylline).

Local Anesthetic The compositions of the present invention may further comprise a safe and effective amount of a local anesthetic. Examples of local anesthetics include benzocaine, lidocaine, bupivacaine, chlorprocaine, dibucaine, etidocaine, mepivacaine, tetracaine, dyclonine, hexylcaine, procaine, cocaine, ketamine, promoxin, phenol, and pharmaceutically acceptable salts thereof. There is salt.

Sunburn Actives The compositions of the present invention may contain a sunburn active. When present, the composition comprises:
Preferably, from about 0.1 to about 20%, more preferably from about 2 to about 7%, and even more preferably from about 3 to about 6% of the composition contains dihydroxyacetone as an artificial tanning active.

Dihydroxyacetone, also known as DHA or 1,3-dihydroxy-2-propanone, is a white to off-white crystalline powder. This material can be represented by the chemical formula C ₃ H ₆ O ₃ and the following chemical structure:

Embedded image The compounds can be present as a mixture of monomers and dimers, with the dimers predominating in the solid crystalline state. Upon heating or melting, the dimer decomposes to give the monomer. This conversion from the dimer form to the monomer form also takes place in aqueous solution. Dihydroxyacetone is furthermore known to be stable at acidic pH values. The Merck Index, 10th
Edition, Item 3167, p. 463 (1983), and "Dihydroxyacetone for Cosmetics", E.I. E. Merck Technical Bulletin, 03-304 110,319 897,1
See 80 588.

Skin Lightening Agent The composition of the present invention may contain a skin lightening agent. When used, the composition comprises:
Preferably from about 0.1 to about 10%, more preferably from about 0.2 to about 5%, more preferably from about 0.5 to about 2%, by weight of the composition, of a skin lightening agent. Suitable skin lightening agents include kojic acid, arbutin, ascorbic acid and derivatives thereof (eg, magnesium ascorbate or sodium phosphate ascorbate), and extracts (eg, mulberry extract, placenta extract) ) And those known in the art. Skin lightening agents suitable for use in the present invention further include PCT
Application No. 95/34280 (Hillebrand), corresponding to PCT Application No. 95/07432 (filed Jun. 12, 1995); and co-pending application Ser. No. 08 / 390,152 (Kbalnes, Kvalnes), Mitchell A.
Mitchell A. DeLong, Burton J. Bradbury (Barton J.
Bradbury), Cartris B.S. No. 95/23780 (filed by Curtis B. Motley), and PCT Application No. 95/23780 (John D. Cart).
er), issued September 8, 1995).

Skin Leveling and Skin Restoring Actives The compositions of the present invention may contain skin leveling or skin restoring actives. Skin smoothing or skin restoring actives suitable for use in the present invention include pantothenic acid derivatives (including panthenol, dexpanthenol, ethyl panthenol), aloe vera, allantoin, bisabolol, and dipotassium glycyrrhizinate Is included. The compositions of the present invention may contain a safe and effective amount of a skin smoothing or skin restoring active, preferably from about 0.1 to about 30% by weight of the composition to be prepared, more preferably Is from about 0.5 to about 20% by weight, even more preferably from about 0.5 to about 20% by weight.
About 10% by weight.

Antimicrobial and antifungal agents The compositions of the present invention may contain antimicrobial or antifungal actives. Such actives can kill microorganisms, prevent the growth of microorganisms, or prevent the pathogenic effects of microorganisms. A safe and effective amount of an anti-bacterial or anti-fungal active is preferably about 0.00 to about 10%, more preferably about 0.01 to about 5%, in a composition of the present invention.
And even more preferably from about 0.05 to about 2%.

Examples of antibacterial and antifungal actives include beta-lactams, quinolones, ciprofloxacin, norfloxacin, tetracycline, erythromycin, amikacin, 2,4,4′-trichloro-2′-hydroxydiphenyl ether, 3
, 4,4'-trichlorovanilide, phenoxyethanol, phenoxypropanol, phenoxyisopropanol, doxycycline, capreomycin,
Chlorhexidine, chlortetracycline, oxytetracycline, clindamycin, ethambutol, hexamidine, isethionate, metronidazole, pentamidine, gentamicin, kanamycin, lineeomycin, metacycline, methenamine, minocycline, neomycin, netilmicin, paromomycin, streptomycin, tobramycin, tobramycin, tetracoline Erythromycin, zinc erythromycin, erythromycin estrate, erythromycin stearate, amikacin sulfate, doxycycline hydrochloride, capreomycin sulfate, chlorhexidine gluconate, chlorhexidine hydrochloride, chlortetracycline hydrochloride, oxytetracycline hydrochloride, clindamycin hydrochloride, ethane hydrochloride Toll, metronidazole hydrochloride, pentamidine hydrochloride, gentamicin sulfate, kanamycin sulfate, lineomycin hydrochloride, metacycline hydrochloride, methenamine hippurate, methenamine mandelate, minocycline hydrochloride, neomycin sulfate, netilmicin sulfate, paromomycin sulfate, streptomycin sulfate, tobramycin sulfate, miconazole hydrochloride , Ketaconazole, amanfazine hydrochloride,
There are amanfazine sulfate, octopirox, parachlorometaxylenol, nystatin, tolnaftate, zinc pyrithione and clotrimazole.

Preferred examples of actives useful herein include salicylic acid, benzoyl peroxide, 3-hydroxybenzoic acid, glycolic acid, lactic acid, 4-hydroxybenzoic acid, acetylsalicylic acid, 2-hydroxybutanoic acid, -Hydroxypentanoic acid, 2-
Hydroxyhexanoic acid, cis-retinoic acid, trans-retinoic acid, retinol, phytic acid, N-acetyl-L-cysteine, lipoic acid, azelaic acid, arachidonic acid, benzoyl peroxide, tetracycline, ibuprofen, naproxen, hydrocortisone, acetimino Phen, resorcinol, phenoxyethanol, phenoxypropanol, phenoxyisopropanol, 2,4,4
'-Trichloro-2'-hydroxydiphenyl ether, 3,4,4'-trichlorocarbanilide, octopirox, lidocaine hydrochloride, clotrimazole,
Includes those selected from the group consisting of miconazole, ketoconazole, neosaicin sulfate, and mixtures thereof.

Exposure to sunscreen actives, ultraviolet radiation, results in excessive scaling and tissue changes of the stratum corneum. Accordingly, the compositions of the present invention may optionally contain a sunscreen active. As used herein, "sunscreen active" includes both sunscreens and physical sunscreens. Suitable sunscreen actives are
It can be organic or inorganic. Inorganic sunscreens useful in the present invention include the following metal oxides: titanium dioxide having an average primary particle size of about 15 to about 100 nm;
5 to about 150 nm, zirconium oxide having an average primary particle size of about 15 to about 150 nm, iron oxide having an average primary particle size of about 15 to about 500 nm, and mixtures thereof. . When used in the present invention, the inorganic sunscreen comprises from about 0.1 to about 20%, preferably from about 0.5 to about 10%, by weight of the composition.
, More preferably about 1 to about 5% by weight.

A wide variety of conventional organic sunscreen actives are suitable for use in the present invention. Sagarin et al., "Cosmetics Science and Technology"
Chnology ")", Chapter VIII, pages 189 et seq. (1972) disclose a number of suitable active substances. Specific, suitable sunscreen actives include, for example; p-aminobenzoic acid, salts and derivatives thereof (ethyl, isobutyl, glyceryl esters; p-dimethylaminobenzoic acid); anthranilates (i.e., o-Aminobenzoic acid; methyl, menthyl, phenyl, benzyl, phenylethyl, linalyl, terpinyl, and cyclohexynyl esters); salicylates (amyl, phenyl, octyl, benzyl, menthyl, glyceryl, and di-propylene glycol esters) ); Cinnamic acid derivatives (menthyl and benzyl esters, α-phenylcinnamonitrile; cinnamoyl butylpyruvate); dihydroxycinnamic acid derivatives (umbelliferone, methylumbelliferone, methylacetoumbelliferone); Cinnamate derivatives (esculetin, methyl esculetin, daphnetin, and glucosides, esculin and Dafunin); hydrocarbons (diphenylbutadiene, stilbene); di benzal acetone and benzal acetophenone; naphthols sulfonates (2-naphthol-3,6
Disulfonic acid and sodium salt of 2-naphthol-6,8-disulfonic acid); di-hydroxynaphthoic acid and its salts; o- and p-hydroxybiphenyldisulfonic acid; coumarin derivatives (7-hydroxy, 7-methyl, 3- Phenyl); diazoles (2-acetyl-3-bromoindazole, phenylbenzoxazole, methylnaphthoxazole, various arylbenzothiazoles); quinine salts (disulfide, sulfate, chloride, oleate, and Quinoline derivatives (8-hydroxyquinoline salts, 2-phenylquinoline); hydroxy- or methoxy-substituted benzophenones; uric acid and violuric acid; tannic acid and its derivatives (eg, hexaethyl ether); Tall) (6-propylpiperonyl) ether Hydroquinone; benzophenones (oxybenzene, Surisobenzen, dioxy benzene, benzo resorcinol, 2,2 '-, 4,4'
-Tetrahydrobenzobenzophenone, 2,2'-dihydroxy-4,4'-dimethoxybenzophenone, octabenzone; 4-isopropyldibenzoylmethane; butylmethoxydibenzoylmethane; ethacrylene; octocrylene;
-(4'-methylbenzylidene borman-2-one), terephthalidene dicamphorsulfonic acid, and 4-isopropyl-di-benzoylmethane.

Among these, 2-ethylhexyl-p-methoxycinnamic acid (Parsol MC
X (commercially available as PARSOL MCX)), 4,4'-t-butylmethoxydibenzoylmethane (commercially available as Parsol 1789), 2-hydroxy-4-methoxybenzophenone, octyldimethyl-p-aminobenzoic acid, diga Loyltrioleate, 2,2-dihydroxy-4-methoxybenzophenone, ethyl-4
-(Bis (hydroxypropyl)) aminobenzoic acid, 2-ethylhexyl-2-
Cyano-3,3-diphenyl acrylate, 2-ethylhexyl salicylate, glyceryl-p-aminobenzoic acid, 3,3,5-tri-methylcyclohexyl salicylate, methyl anthranilate, p-dimethylaminobenzoic acid or aminobenzoic acid 2-ethylhexyl-p-dimethylaminobenzoic acid, 2-phenylbenzimidazole-5-sulfonic acid, 2- (p-dimethylaminophenyl) -5-sulfonebenzoxazoic acid, octocrylene and a mixture of these compounds. preferable.

Further preferred organic sunscreen actives useful in compositions useful in the present invention are 2
-Ethylhexyl-p-methoxycinnamate, butylmethoxydibenzoyl-methane, 2-hydroxy-4-methoxybenzophenone, 2-phenylbenzimidazole-5-sulfonic acid, octyldimethyl-p-aminobenzoic acid, octocrylene and the like It is a mixture.

Among the compositions, more particularly useful are US Pat. No. 4,937,370 (Sabatelli, issued Jun. 26, 1990), and US Pat. No. 4,999.
No. 186 (Spirnak, March 12, 1991). The sunscreen disclosed therein has two distinct chromophore moieties that exhibit different ultraviolet absorption spectra in a single molecule. One of the chromophores absorbs mainly in the UVB emission range and the other absorbs strongly in the UVA emission range.

Preferred for this type of sunscreen are 4-N, N- (2-ethylhexyl) methylaminobenzoic acid ester of 2,4-dihydroxybenzophenone; N, N-dibenzoate with 4-hydroxydibenzoylmethane -(2-ethylhexyl) -4-aminobenzoic acid ester; 4-hydroxydibenzoylmethane
-N, N- (2-ethylhexyl) methylaminobenzoic acid ester; 4-N, N- (2-ethylhexyl) methylaminobenzoic acid ester of 2-hydroxy-4- (2-hydroxyethoxy) benzophenone; 4- ( 4-N, N- (2-ethylhexyl) -methylaminobenzoic acid ester of 2-hydroxyethoxy) dibenzoylmethane; N, N-di- (2- (2-hydroxy-4- (2-hydroxyethoxy) benzophenone) Ethylhexyl) -4-aminobenzoic acid ester; and N, N-di- (2-ethylhexyl) -4-aminobenzoic acid ester of 4- (2-hydroxyethoxy) dibenzoylmethane and mixtures thereof.

Particularly preferred sunscreen actives include 4,4′-t-butylmethoxydibenzoylmethane, 2-ethylhexyl-p-methoxycinnamate, phenylbenzimidazole sulfonic acid, and octocrylene. A safe and effective amount of an organic sunscreen active is one of the compositions, typically about 1%.
About 20%, more typically about 2% to about 10%. The exact amount depends on the sunscreen or sunscreens selected and the desired sun protection index (
SPF).

[0070] The composition of the particulate matter present invention, particulate material, preferably may contain metal oxides. These particles may have a textured or untextured surface, and may be charged or uncharged. For charged particulate matter, see US Pat. No. 5,997,8.
No. 87 (Ha et al.), Which is incorporated herein by reference. Particulate materials useful herein include: bismuth oxychloride, iron oxide, mica, mica treated with barium sulfate and TiO2, silica, nylon, polyethylene, talc, styrene, polypropylene, copolymers of ethylene / acrylic acid, Titanium dioxide, iron oxide, bismuth oxychloride, sericite, aluminum oxide, silicone resin, barium sulfate, calcium carbonate, cellulose acetate,
Polymethyl methacrylate, and mixtures thereof. Inorganic particulate matter, such as TiO2, ZnO, or ZrO2, is commercially available from a number of sources. One example of a suitable particulate material is disclosed in US Pat. S. Substances available from US Cosmetics (TRONOX TiO2 series, SAT-T CR837)
, Rutile TiO2). Preferably, the particulate matter is present in the composition from about 0.01% to about 2%, more preferably from about 0.05% to about 1.5%, even more preferably from about 0.1% to about 1.5%, by weight of the composition. It is present at a concentration of 1% by weight.

Conditioning Agent The compositions of the present invention may contain a conditioning agent selected from humectants, humectants, or skin conditioners. These various materials can be used, each of which comprises from about 0.01% to about 20%, more preferably from about 0.1% to about 10%, and even more preferably from about 0.1% by weight of the composition. It may be present as from about 5 to about 7% by weight. These materials include guanidine; urea; glycolic acid and glycolate (eg, ammonium and quaternary alkyl ammonium); salicylic acid; lactic acid and lactate (eg, ammonium and quaternary alkyl ammonium); Aloe vera (eg, aloe vera gel); polyhydric alcohols such as sorbitol, mannitol, xylitol, erythritol, glycerol, hexanetriol, butanetriol, propylene glycol, butylene glycol, hexylene glycol, etc .; polyethylene glycol; (Eg, melibiose) and starch; sugars and starch derivatives (eg, alkoxylated glucose, fructose, glucosamine); hyaluronic acid; lactamide monoethanolamine; Seto amide monoethanolamine; panthenol; allantoin; and although mixtures thereof, without limitation. More useful herein are U.S. Pat. No. 4,976,953 (Or).
r) et al., issued December 11, 1990).

Further useful are monoesters and polyesters of various C ₁ -C ₃₀ saccharides and related materials. Such esters are derived from sugar or polyhydric alcohol moieties and one or more carboxylic acid moieties. Such ester materials are described in U.S. Pat. No. 2,831,854, U.S. Pat. No. 4,005,196 (Jandacek, issued Jan. 25, 1977); U.S. Pat.
No. 195 (Jandasek, issued Jan. 25, 1977), US Pat. No. 5,306
No. 5,516 (Letton et al., Issued April 26, 1994);
U.S. Patent No. 5,306,515 (Reton et al., Issued April 26, 1994);
305,514 (Reton et al., Issued April 26, 1994); U.S. Pat.
No. 7,300 (Jandasek et al., Issued Jan. 10, 1989); U.S. Pat.
No. 963,699 (Rizzi et al., Issued June 15, 1976); US Pat. No. 4,518,772 (Volpenhein, issued May 21, 1985); and US Pat. No. 517, 360 (Volpenhain, 198
(Issued May 21, 2005). Preferably, the conditioning agent is selected from urea, guanidine, sucrose polyester, panthenol, dexpanthenol, allantoin, and mixtures thereof.

Constituents The compositions of the present invention, and especially the emulsions of the present invention, may contain constituents. The constituents in the oil-in-water emulsions of the present invention are particularly preferred. Without being bound by theory, it is believed that the constituents help provide rheological properties to the composition that provide stability of the composition. For example, the constituents tend to help form a liquid crystal gel network. Constituents may also function as emulsifiers or surfactants. Preferred compositions of the present invention comprise from about 0.1 to about 20%, more preferably from about 0.1 to about 20%.
It contains from about 10% to even more preferably from about 0.5% to about 9% of one or more components.

Preferred components have an HLB of about 1 to about 8 and a melting point of at least about 45 ° C.
Have. Preferred components are saturated C₁₄~ C₃₀Aliphatic alcohol, from about 1 to about 5 moles
Saturated C containing ethylene oxide₁₆~ C₃₀Aliphatic alcohol, saturated C₁₆~ C₃₀ Diol, saturated C₁₆~ C₃₀Monoglycerol ether, saturated C₁₆~ C₃₀Hydroxy
C fatty acid, C₁₄~ C₃₀Hydroxylated and non-hydroxylated saturated fatty acids, C₁₄~
C₃₀Saturated ethoxylated fatty acids, containing about 1 to about 5 moles of ethylene oxide diol
Amines, alcohols and monoglycerides containing at least 40% C ₁₄ ~ C₃₀Saturated glyceryl monoester, about 1 to about 3 alkyl groups and about 2 to about
C having three saturated glycerol units₁₄~ C₃₀Saturated polyglycerols
Tell, C₁₄~ C₃₀Glyceryl monoether, C₁₄~ C₃₀Sorbitan mono / jee
Stell, C with about 1 to about 5 moles of ethylene oxide₁₄~ C₃₀Saturated ethoxylation
Sorbitan mono / diester, C₁₄~ C₃₀Saturated methyl glucoside ester of C ₁₄ ~ C₃₀Of saturated sucrose monoester / diester, about 1 to about 5 moles of ethyl
With oxide₁₄~ C₃₀Of saturated ethoxylated methyl glucoside ester,
C having an average of 1-2 glucose units₁₄~ C₃₀A saturated polyglucoside and
It is selected from a mixture thereof and has a melting point of at least about 45 ° C.

Preferred components of the present invention are stearic acid, palmitic acid, stearyl alcohol, cetyl alcohol, behenyl alcohol, stearic acid, palmitic acid,
The polyethylene glycol ether of stearyl alcohol having an average of about 1 to about 5 ethylene oxide units, the polyethylene glycol ether of cetyl alcohol having an average of about 1 to about 5 ethylene oxide units, and mixtures thereof. Further preferred components of the present invention are stearyl alcohol, cetyl alcohol, behenyl alcohol, polyethylene glycol ether of stearyl alcohol having an average of about 2 ethylene oxide units (Steares-2), and cetyl alcohol having an average of about 2 ethylene oxide units. It is selected from polyethylene glycol ethers, and mixtures thereof. Still more preferred components are stearic acid, palmitic acid, stearyl alcohol,
It is selected from cetyl alcohol, behenyl alcohol, steareth-2, and mixtures thereof.

Thickener Components (Including Thickeners and Gelling Agents) The compositions of the present invention preferably comprise from about 0.1% to about 5%, more preferably from about 0.1% to about 5%, by weight of the composition. 4% by weight, and even more preferably about 0.25 to about 3% by weight of 1
It may contain one or more thickener components. Thickener components include, but are not limited to, those selected from:

A) Carboxylic Acid Polymers These polymers are cross-linked compounds containing acrylic acid, substituted acrylic acid, and one or more monomers derived from such acrylic acid or salts and esters of such substituted acrylic acid. Wherein the crosslinking agent comprises two or more carbon-carbon double bonds,
And derived from polyhydric alcohols. For polymers useful in the present invention, see U.S. Pat. No. 5,087,445 (Haffey et al., Issued Feb. 11, 1992).
U.S. Patent No. 4,509,949 (Huang et al., Issued April 5, 1985); U.S. Patent No. 2,798,053 (Brown, July 1957);
Issued on March 2); and CTFA International Cosmeti
c Ingredient Dictionary), 4th edition, pages 12 and 80 (1991).

Examples of commercially available carboxylic acid polymers useful herein include sucrose
Of acrylic acid crosslinked with allyl ether or pentaerythritol
Carbomer. This carbomer is Carbopol (registered)
(Registered trademark) 900 series (for example, Carbopol (registered trademark) 954) B
. F. Available from B.F. Goodrich. In addition to that,
Other suitable carboxylic acid polymerizing agents include C_10-30Alkyl acrylate and one or
A plurality of acrylic acid monomers, methacrylic acid monomers, or one of their short chains (
That is, C_1-4Alcohol) with its ester
The agent is an allyl ether of sucrose or pentaerythritol. These
The polymer is acrylate / C_10-30Alkyl acrylate crosspolymer
Known, usually Carbopol® 1342, Carbopol
(Registered trademark) 1382, Pemulen TR-1, and Pemulen TR-
2 as B. F. Commercially available from Goodrich. In other words, in this specification
Examples of useful carboxylic acid polymer thickeners are carbomer, acrylate / C_Ten~ C ₃₀ Also selected from alkyl acrylate crosspolymers and mixtures thereof
It is.

B) Crosslinked Polyacrylate Polymers The compositions of the present invention can be used as effective thickeners or gelling agents to include crosslinked polyacrylate polymers, including both cationic and nonionic polymers, usually the preferred cationic Arbitrarily. For examples of useful crosslinked nonionic polyacrylate polymers and crosslinked cationic polyacrylate polymers, see US Pat. No. 5,100,660 (Hawe et al., Issued Mar. 31, 1992); U.S. Patent No. 4,849,484 (Heard, issued July 18, 1989); U.S. Patent No. 4,835,206 (Farrar et al., 19).
U.S. Pat. No. 4,628,078 (Glover).
Et al., Issued Dec. 9, 1986); U.S. Pat. No. 4,599,379 (Flesher et al., Issued Jul. 8, 1986); and EP 228,868 (Farra et al., Jul. 1987). On March 15).

C) Polyacrylamide Polymer The compositions of the present invention may optionally contain a polyacrylamide polymer, especially a non-ionic polyacrylamide polymer, including substituted branched or unbranched polymers. Of these polyacrylamide polymers, more preferred are nonionic polymers, polyacrylamide and isoparaffin and laureth 7 under the CTFA name, sold under the trade name Sepigel 305 by Seppic Corporation, New Jersey, USA Fairfield). Another polyacrylamide polymer useful in the present invention is a multi-block copolymer of acrylamide, acrylamide substituted with acrylic acid, and substituted acrylic acid. Examples of commercial products of such multi-block copolymers include Hypan SR150H, SS500V, SS500W from Lipo Chemicals, Inc., Patterson, NJ, USA.
SSSA100H.

D) Polysaccharides A wide variety of polysaccharides are useful herein. "Polysaccharide" refers to a gelling agent containing a main chain of repeating sugar (ie, carbohydrate) units. Examples of polysaccharide gelling agents include cellulose, carboxymethylhydroxyethylcellulose, cellulose acetate propionate carboxylate, hydroxyethylcellulose, hydroxyethylethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, methylhydroxyethylcellulose, microcrystalline cellulose, and cellulose sulfate. Sodium, and mixtures thereof, but are not limited thereto. Cellulose substituted with an alkyl group is also useful herein. In these polymers, the hydroxy groups of the cellulose polymer are hydroxyalkylated (preferably hydroxyethylated or hydroxypropylated) to form a hydroxyalkylated cellulose, which is then further converted to a C ₁₀ -C ₃₀ linear or branched chain. The alkyl group is modified via an ether bond. Typically these polymers are ethers of straight-chain or branched-chain alcohols hydroxyalkyl cellulose C ₁₀ -C _30. Examples of alkyl groups useful herein are stearyl, isostearyl, lauryl, myristyl, cetyl, isocetyl, coconut oil (ie, alkyl groups derived from the alcohols of coconut oil).
, Palmityl, oleyl, linoleyl, linolenil, ricinoleyl, behenyl,
And mixtures thereof. Preferred among the alkyl hydroxyalkyl cellulose ethers are substances whose CTFA name is cetyl hydroxyethyl cellulose, which is an ether of cetyl alcohol and hydroxyethyl cellulose. This material is commercially available from Aqualon Corporation (Wilmington, Del.) Under the trade name Natrosol® under the trademark CS Plus. Other useful polysaccharides include scleroglucans, in which (1-6) linked glucose binds every 3 units of linear (1-3) linked glucose units, Examples obtained in commercial products include: Michael Mercier Products In
c.) Clearogel® CS11 (Mountainside, NJ).

E) Rubber Other thickening and gelling agents useful herein include substances derived primarily from natural resources. Examples of these gelling gums include gum arabic, agar, alginate, alginic acid, ammonium alginate, amylopectin, calcium alginate, carrageenan calcium, carnitine, carrageenan, dextrin, gelatin, gellan gum, guar gum, hydroxypropyltrimonium chloride guar, Hectorite, hyaluronic acid, silicic acid, hydroxypropyl chitosan, hydroxypropyl guar, karaya gum, kelp, locust bean gum, natto gum, potassium alginate, carrageenan potassium, propylene glycol alginate, sclerotium gum, carboxymethyl dextran sodium, carrageenan sodium, Examples include, but are not limited to, tragacanth gum, xanthan gum, and mixtures thereof. Preferred compositions of the present invention include a thickener component selected from carboxylic acid polymers, crosslinked polyacrylate polymers, polyacrylamide polymers, and mixtures thereof, and more preferably selected from polyacrylamide polymers, and mixtures thereof. Carboxylic acid polymers are included.

IV. Dermatologically Acceptable Carrier The topical compositions of the present invention further comprise a dermatologically acceptable carrier.
As used herein, the phrase "dermatologically acceptable carrier" means that the carrier is suitable for topical application to keratinous tissue, has aesthetically pleasing properties, It means that the active substance and any other components are compatible and do not cause any untoward or toxic related for safety. A safe and effective amount of carrier is from about 50% to about 99.99%, preferably about 80%, of the composition.
To about 99.9%, more preferably about 90 to about 98%, and even more preferably about 90 to about 95%. The carrier can take a variety of forms. For example, emulsion carriers such as an oil-in-water emulsion, a water-in-oil emulsion, a water-in-oil-in-water emulsion, and an oil-in-water-in-silicone emulsion are useful in the present invention, but are not limited thereto.

Preferred carriers include emulsions such as oil-in-water emulsions, water-in-oil emulsions, and water-in-silicone emulsions. As will be appreciated by those skilled in the art, any component will first enter the water or oil / silicone phase, depending on the solubility / dispersibility of the component in the composition in water. Oil-in-water emulsions are particularly preferred.

Emulsions according to the invention generally contain the abovementioned solutions and lipids or oils. Lipids and oils may be derived from animals, plants or petroleum and may be natural or synthetic (artificial). Preferred emulsions further contain a humectant such as glycerin. The emulsion preferably contains from about 0.01% to about 10%, more preferably from about 0.1% to about 5%, of the emulsifier, based on the weight of the carrier. The emulsifier is
It can be non-ionic, anionic, or cationic. Suitable emulsifiers are described, for example, in US Pat. No. 3,755,560 (Dickert et al., August 1973).
U.S. Pat. No. 4,421,769 (Dixon et al.
Published December 20, 1983); and Makkachan's "Cleaning and Emulsifying Agents (McCu
tcheon's Detergents and Emulsifiers) ", North American version, 317-324 (19
1986). The emulsion may further contain an antifoaming agent that minimizes foaming when applied to keratinous tissue. Antifoaming agents include high molecular weight silicones and other materials well known in the art to utilize as such. Suitable emulsions can have a wide range of viscosities, depending on the desired product form. Exemplary preferred low viscosity emulsions have a viscosity of about 50 centistokes or less, more preferably about 10 centistokes or less, even more preferably about 5 centistokes or less. For preferred water-in-silicone emulsions and oil-in-water emulsions,
The details are described below.

A) Water-in- silicone emulsion The water-in- silicone emulsion contains a silicone continuous phase and an aqueous dispersed phase. (1) Preferred water-in-silicone emulsions of silicone continuous phase present invention is from about 1 to about 60 wt%, preferably from about 5 to about 40 wt%, more preferably from about 10 to about 20 wt% silicone continuous phase contains. The silicone continuous phase contains or exists as an external phase that contains or surrounds the discontinuous aqueous phase as described below. The silicone continuous phase contains a polyorganosiloxane oil. Preferred water-in-silicone emulsion systems are formulated to provide an oxidatively stable solvent for the retinoid. The silicone continuous phase of these preferred emulsions contains from about 50 to about 99.9% by weight of the organopolysiloxane oil and less than about 50% by weight of the non-silicone oil. In a particularly preferred embodiment, the silicone continuous phase comprises at least about 50% by weight of the silicone continuous phase, preferably from about 60 to 60%.
About 99.9 wt%, more preferably about 70 to about 99.9 wt%, and even more preferably about 80 to about 99.9 wt% polyorganosiloxane oil, and less than about 50 wt% of the silicone continuous phase. Preferably, it contains less than about 40%, more preferably less than about 30%, even more preferably less than about 10%, and even more preferably less than about 2% by weight of a non-silicone oil. Such preferred emulsion systems have higher oxidative stability to retinoids for longer periods of time than water-in-oil emulsions containing only low concentrations of polyorganosiloxane oil.
Non-silicone oils in the silicone continuous phase are minimized or eliminated altogether to further enhance the oxidative stability of the selected retinoid in the composition. This type of water-in-silicone emulsion is described in PCT application WO 97/214
23 (issued June 19, 1997).

The organopolysiloxane oil used in the composition can be volatile, non-volatile, or a mixture of volatile and non-volatile silicones. The term "non-volatile" as used in this context refers to a silicone that is liquid at ambient conditions and has a flash point of about 100 ° C. or higher (at 1 atmosphere). The term "volatile" as used in this context refers to all other silicone oils. Suitable organopolysiloxanes can be selected from a wide variety of silicones having a wide range of volatility and viscosity. Examples of suitable organopolysiloxane oils include polyalkyl siloxanes, cyclic polyalkyl siloxanes and polyalkylaryl siloxanes.

[0088] Polyalkylsiloxanes useful in the compositions of the present invention include, at 25 ° C, about 0.5 to 1
It contains a polyalkylsiloxane having a viscosity of 1,000,000 centistokes. The general chemical formula of such a polyalkylsiloxane is represented by R ₃ SiO [R ₂ SiO] _x SiR _3, where R is an alkyl group having 1 to about 30 carbon atoms (preferably R is a methyl group or An ethyl group, more preferably a methyl group; further mixed alkyl groups may be used in the same molecule) and x is from 0 to about 10,
Is an integer of 000 and is selected to obtain the desired molecular weight in a range that can exceed about 10,000,000. Commercially available polyalkylsiloxanes include polydimethylsiloxanes, also known as dimethicones, examples of which are the Vicasil® series and Dow Corning. Corporation (Dow Corning Corpor
ation) commercially available from Dow Corning® 200 series. A specific example of a suitable polydimethylsiloxane has a viscosity of 0.65
Dow Corning® 200 liquid having a centistokes boiling point of 100 ° C., a Dow Corning® liquid having a viscosity of 10 centistokes and a boiling point exceeding 200 ° C.
Corning® 225 liquid and viscosities of 50, 350 and 1 respectively
Dow Corning with boiling point above 200 ° C at 2,500 centistokes
Corning) ® 200 solution. Suitable dimethicones include those of the formula (CH ₃ ) ₃ SiO [(CH ₃ ) ₂ SiO] _x [CH ₃ RSiO] _y Si (CH ₃ ) ₃
Wherein R is straight or branched chain alkyl having 2 to about 30 carbon atoms, x and y are each an integer of 1 or greater, and about 10,000 It is selected to obtain the desired molecular weight in the range that can exceed 2,000. Examples of these alkyl-substituted dimethicones include cetyl dimethicone and lauryl dimethicone.

The cyclic polyalkylsiloxanes suitable for use in the above compositions include those of the formula [S
iR ₂ —O] _n , wherein R is an alkyl group (preferably R is a methyl or ethyl group, more preferably a methyl group) and n is from about 3 to about 8,
More preferably it is an integer from about 3 to about 7, most preferably from about 4 to about 6. R
When is a methyl group, these substances are typically referred to as cyclomethicones. Commercially available cyclomethicone has a Dow Corning® 244 liquid containing 2.5 centistokes viscosity and a boiling point of 172 ° C. containing primarily cyclomethicone tetramer (ie, n = 4), a viscosity of 2.5 Boiling point is 178 ℃ in centistokes
Dow Corning® 344 liquid containing a predominantly cyclomethicone pentamer (ie, n = 5) having a viscosity of 4.2 centistokes and a boiling point of 205.
Dow Corning® 245 liquid, which is a mixture of predominantly cyclomethicone tetramers and pentamers (ie, n = 4 and 5) at ℃, and a viscosity of 4.
Includes Dow Corning® 345 liquid, which is a predominantly chloromethicone tetramer, pentamer, and hexamer (ie, n = 4, 5, and 6) with a boiling point of 217 ° C. at 5 centistokes.

More effective ones correspond to the general chemical formula [(CH ₂ ) ₃ SiO _1/2 ] _x [SiO ₂ ] y, where x is an integer from about 1 to about 500 and y is about 1 Materials such as trimethylsiloxysilicate, a polymeric material that is an integer from about 500. Commercially available trimethylsiloxysilicate is sold as Dow Corning® 593 liquid as a mixture with dimethicone.

Dimethiconol is also suitable for use in the composition. Such compounds have the formula R ₃ SiO [R ₂ SiO] _x SiR ₂ OH and HOR ₂ SiO [R ₂ SiO] _x Si
R can be represented by R ₂ OH, where R is an alkyl group (preferably R is a methyl or ethyl group, more preferably a methyl group) and x is from 0 to about 500 selected to obtain the desired molecular weight. Is an integer up to. Commercially available dimethiconol is typically sold as a mixture with dimethicone or cyclomethicone (eg, Dow Corning® solutions 1401, 1402, and 1403).

[0092] Polyalkylaryl siloxanes are also suitable for use in the composition. 25
Polymethylphenylsiloxanes having a viscosity of from about 15 to about 65 centistokes at C are particularly useful. Preferred for use in the present invention are organopolysiloxanes selected from polyalkylsiloxanes, alkyl-substituted dimethicones, cyclomethicones, trimethylsiloxysilicates, dimethiconols, polyalkylarylsiloxanes, and mixtures thereof. Also preferred for use in the present invention are polyalkylsiloxanes and cyclomethicones. Preferred among the polyalkylsiloxanes is dimethicone.

[0093] As mentioned above, the silicone continuous phase may contain one or more non-silicone oils. Non-silicone oils in the continuous silicone phase are avoided at minimum concentrations or mixed to further enhance the oxidative stability of the selected retinoid in the composition. A preferred non-silicone oil is about 1 atmosphere and about 25 ° C.
It has the following melting point: Examples of non-silicone oils suitable for use in the silicone continuous phase include, for example, mineral oils, vegetable oils, synthetic oils, semi-synthetic oils and the like used in topical personal care products well known to those skilled in the chemical arts. In the form of a water-in-oil emulsion.

[0094] (2) The composition of topical application of the aqueous dispersion phase present invention is from about 30 to about 90%, more preferably from about 50 to about 85%, and even more preferably from about 70 to about 80% aqueous dispersion Phase. In emulsion technology, the term "dispersed phase" is a term well known to those skilled in the art,
It means that the phase is present as small particles or droplets suspended or surrounded by the continuous phase. Dispersed phases are also known as internal or discontinuous phases. The aqueous phase dispersion is a dispersion of small aqueous particles or droplets suspended or surrounded by the continuous silicone phase described above. The aqueous phase can be water or a combination of water and one or more water-soluble or water-dispersible components. Examples of such components include thickeners, acids, bases, salts, chelating agents, gums, water-soluble or dispersible alcohols and polyols, buffers,
Includes, but is not limited to, preservatives, sunscreens, coloring agents and the like. The topical compositions of the present invention typically comprise from about 25% to about 90%, preferably from about 40% to about 80%, more preferably from about 60% to about 80%, by weight of the composition, of the aqueous dispersion phase. Contains water.

(3) Emulsifier Dispersing Aqueous Phase The water-in-silicone emulsion of the present invention preferably contains an emulsifier. In a preferred embodiment, the composition comprises from about 0.1 to about 10%, more preferably from about 0.5 to about 7.5%, even more preferably from about 1 to about 5%, of the emulsifier by weight of the composition. It contains. Emulsifiers help disperse and suspend the aqueous phase in the continuous silicone phase.

A wide variety of emulsifiers can be used in the present invention to prepare the preferred water-in-silicone emulsions. Known or conventional emulsifiers can be used in the composition provided that the emulsifier chosen is chemically and physically compatible with the components of the composition of the invention, and the desired dispersing properties can be obtained. Bring. Suitable emulsifiers include silicone emulsifiers, non-silicone containing emulsifiers, and mixtures thereof, well known to those skilled in the art for use in topical personal care products. Preferably, these emulsifiers have an HLB value of about 14 or less, more preferably about 2 to about 14, and even more preferably about 4 to about 14. Emulsifiers with HLB values outside these ranges may be used in combination with other emulsifiers so that the effective weighted average value of the HLB falls within these ranges.

[0097] Silicone emulsifiers are preferred. A wide variety of silicone emulsifiers are useful in the present invention. Such silicone emulsifiers are generally organically modified organopolysiloxanes, also known to those skilled in the art as silicone surfactants. Effective silicone emulsifiers include dimethicone copolyol. These materials may contain polyether side chains such as, for example, polyethylene oxide chains, polypropylene oxide chains, mixtures of these molecular chains, and polyether chains containing moieties derived from both ethylene oxide and propylene oxide. Is a modified polydimethylsiloxane. Other examples include alkyl-modified dimethicone copolyols, ie, compounds containing C ₂ -C ₃₀ pendant side chains. Still other useful dimethicone copolyols include materials having various cations, anions, zwitterions, and zwitter pendant moieties.

The dimethicone copolyol emulsifiers useful in the present invention can be described by the following general structure:

Embedded image

In this case, R is a C _{1 to} C ₃₀ linear, branched or cyclic alkyl group, and R ² is selected from the group consisting of: _{- (CH 2) n -O- (} CH 2 CHR 3 O) m -H, and _{- (CH 2) n -O- (} CH 2 CHR 3 O) m - (CH 2 CHR 4 O) o-H, Wherein n is an integer from 3 to about 10; R ³ and R ⁴ are H and C ₁ -C ₆ linear or branched such that R ³ and R ⁴ are not simultaneously the same. M, o, x, and y are selected such that the overall molecular weight is from about 200 to about 10,000,000, and m, o, x, and y are selected from the group consisting of: , M and o are each independently selected from integers greater than or equal to zero so that they are not simultaneously zero, and z is selected from another integer greater than or equal to one. It is recognized that regioisomers of these copolyols can be formed. The chemical representatives described above for the R ² moiety containing R ³ and R ⁴ groups are provided for convenience and are not limiting.

Also useful herein are silicone surfactants, although not strictly classified as dimethicone copolyols, such as the structure shown in the preceding paragraph, wherein R ² is: CH ₂ ) _n —O—R ⁵ , where R ⁵ is a cation, anion, zwitterion or zwitterionic moiety.

Examples of dimethicone copolyols and other silicone surfactants useful as emulsifiers in the present invention include polydimethylsiloxane polyether copolymers with pendant polyethylene oxide side chains, polydimethyl siloxane polyether copolymers with pendant polypropylene oxide side chains. Dimethylsiloxane polyether copolymer, polydimethylsiloxane polyether copolymer with mixed pendant of polyethylene and polypropylene side chains, polydimethylsiloxane polyether copolymer with pendant mixture of poly (ethylene) (propylene) oxide side chains, pendant Polydimethylsiloxane polyether copolymer with organobetaine side chains, polydimethylsiloxane polyether copolymer with pendant carboxylic acid side chains Polydimethylsiloxane polyether copolymers with pendant quaternary ammonium side chains; and copolymers further modified during the synthesis, containing pendant C ₂ -C ₃₀ linear, branched or cyclic alkyl moieties. Including, but not limited to. Examples of dimethicone copolyols sold by Dow Corning Corporation useful herein are Dow Corning® 190,193, Q2-5220, 250
1 wax, 2-5324 liquid, and 3225C (this latter material is sold as a mixture with cyclomethicone). Cetyl dimethicone copolyol is commercially available as a mixture of polyglyceryl-4-isostearate (and) hexyl laurate and sold under the trade name ABIL® WE-09 (from Goldschmidt). In addition, cetyl dimethicone copolyol is commercially available as a mixture of hexyl laurate (and) polyglyceryl-3-oleate (and) cetyl dimethicone and has the tradename ABIL® WS-
08 (from Goldschmidt). Other examples of dimethicone copolyols include lauryl dimethicone copolyol, dimethicone copolyol acetate, dimethicone copolyol adipate, dimethicone copolyolamine, dimethicone copolyol behenate, dimethicone copolyol Butyl ether, dimethicone copolyol hydroxystearate, dimethicone copolyol isostearate, dimethicone copolyol laurate, dimethicone copolyol methyl ether, dimethicone copolyol phosphate, and include dimethicone copolyol stearate, It is not limited to these. International Cosmetic Ingredients Dictionary (International Cosm
etic Ingredient Dictionary), 5th edition (1993).

Dimethicone copolyol emulsifiers useful in the present invention include, for example, US Pat.
960,764 (Figueroa, Jr., issued Oct. 2, 1990); European Patent No. EP 330,369 (SanoGueira),
G., published August 30, 1989); H. "New Formulation Possibi offered by silicone copolyols," by Dahms et al.
lities Offered by Silicone Copolyols ") Cosmetics and toiletries
& Toiletries) 110, 91-100, March 1995; E. FIG. "Optimization of W / OS emulsions and study of quantitative relationship between ester structure and emulsion properties" by Carlotti et al. ("Optimization of W / OS Emulsions A"
nd Study Of The Quantitative Relationships Between Ester Structure And E
mulsion Properties ") J. Dispersion Science And Technolog
y), Vol. 13, No. 3, pp. 315-336 (1992); Hameyer
) "Comparative Technological Investigations of Organic": Organic and Organic Silicone Emulsifiers in the Preparation of Cosmetics and Water-in-Oil Emulsions
and Organosilicone Emulsifiers in Cosmetic Water-in-Oil Emulsion Prepar
ations "), HAPPI, Vol. 128, No. 4, pp. 88-128 (1991);
"Efficiency and usability of silicone surfacta" by Smid-Korbar et al., "Efficacy and usability of silicone surfactants in emulsions."
nts in emulsions "), Provisional Communications, International Journal of Cosmetic Science (Provisional Communic
ation, International Journal of Cosmetic Science), Volume 12, 135-13
9 (1990); G. FIG. "A New Silicone Emulsifier For Water" by Krzysik et al., "A New Silicone Emulsifier for Water-in-Oil Systems"
-in-Oil Systems "), Drug and Cosmetic Industry (Dr.
ug and Cosmetic Industry), Vol. 146, No. 4, pp. 28-81 (April 1990)
It is described in.

[0103] Among the non-silicone-containing emulsifiers useful in the present invention, sugar esters and polyesters, alkoxylated sugar esters and _{polyesters, C 1 ~C 30 C 1 ~C} 30 fatty acid esters of aliphatic alcohols, C ₁ -C ₃₀ alkoxylated derivatives of C ₁ -C ₃₀ fatty acid esters of fatty alcohols, C ₁ -C ₃₀ alkoxylated ethers of fatty alcohols, C ₁ -C ₃₀ polyglyceryl esters of fatty acids, C ₁ -C ₃₀ esters of polyols, polyol C ₁ -C ₃₀ ethers, alkyl phosphates, polyoxyalkylene fatty ether phosphates, fatty acid amides, acyl lactylates, there are various non-ionic and anionic emulsifiers, such as soaps, and mixtures thereof.
Other suitable emulsifiers are described, for example, in Makkachan's "Cleaners and Emulsifiers" (McCutc
heon's, Detergents and Emulsifiers), North America, 1986, Allred
Published by Allured Publishing Corporation; U.S. Patent No. 5,011,681 (Ciotti et al., April 1991).
U.S. Pat. No. 4,421,769 (Dixon et al., December 1983).
And U.S. Pat. No. 3,755,560 (Dicker).
t) et al., issued August 28, 1973).

These non-silicone containing emulsifiers include polyethylene glycol-20-sorbitan monolaurate (polysorbate-20), polyethylene glycol-5
-Soy Sterol, Steareth-20, Ceteareth-2
0, PPG-2-methyl glucose ether distearate, Ceteth-
10, Polysorbate-80, cetyl phosphate, potassium cetyl phosphate, diethanolamine cetyl phosphate, polysorbate-60,
Glyceryl stearate, PEG-100-stearate, polyoxyethylene-20-sorbitan trioleate (polysorbate 85), sorbitan monolaurate, polyoxyethylene-4-lauryl ether sodium stearate, polyglyceryl-4-isostearate, Hexyl laurate, steareth-
20, ceteareth-20, PPG-2-methylglucose ether distearate, ceteth-10, diethanolamine cetyl phosphate, glyceryl stearate, PEG-100-stearate, and mixtures thereof, but are not limited thereto.

B) Oil-in-water emulsions and other preferred topical carriers include oil-in-water emulsions having a continuous aqueous phase and a water-insoluble phase dispersed therein (the “oil phase”). Examples of suitable oil-in-water emulsion carriers are described in US Pat. No. 5,073,371 (Turner (
Turner); J. Et al., Issued December 17, 1991) and U.S. Pat.
73, 372 (Turner, DJ et al., Issued December 17, 1991). Particularly preferred oil-in-water emulsions containing a component, a hydrophilic surfactant, and water are described in detail below.

(1) Constituents Preferred oil-in-water emulsions contain constituents and aid in the formation of a crystalline gel network. Without being bound by theory, it is believed that the constituents help provide the composition with rheological properties that contribute to the stability of the composition. Constituents may also function as emulsifiers or surfactants. Preferred compositions of the present invention contain from about 0.5% to about 20%, more preferably from about 1% to about 10%, even more preferably from about 1% to about 5%, by weight of the composition, of a component.

Preferred components of the present invention include stearic acid, palmitic acid, stearyl alcohol, cetyl alcohol, behenyl alcohol, stearic acid, palmitic acid, polyethylene glycol ether of stearyl alcohol having an average of about 1 to about 21 ethylene oxide units. And polyethylene glycol ethers of cetyl alcohol having an average of about 1 to about 5 ethylene oxide units, and mixtures thereof. Further preferred components of the present invention include stearyl alcohol, cetyl alcohol, behenyl alcohol, polyethylene glycol ether of stearyl alcohol having an average of about 2 ethylene oxide units (Steares-2), and stearyl alcohol having an average of about 21 ethylene oxide units. It is selected from polyethylene glycol ethers (Steareth-21), polyethylene glycol ethers of cetyl alcohol having an average of about 2 ethylene oxide units, and mixtures thereof. Even more preferred constituents are selected from stearic acid, palmitic acid, stearyl alcohol, cetyl alcohol, behenyl alcohol, steareth-2, steareth-21, and mixtures thereof.

(2) Hydrophilic surfactant A preferred oil-in-water emulsion is about 0.05 to about 10%, preferably about 1 to 1%.
About 6%, and more preferably about 1 to about 3%, of at least one hydrophilic surfactant capable of dispersing the hydrophobic substance in the aqueous phase (by weight percent of the topical carrier). The surfactant must at least have sufficient hydrophilicity to disperse in water.

[0109] Preferred hydrophilic surfactants are selected from non-ionic surfactants. Among the nonionic surfactants, those useful in the present invention include long chain alcohols such as _C8-30.
It can be broadly defined as the condensation product of an alcohol with a sugar or a starch polymer or glycoside. Such compounds can be represented by the formula (S) _n -OR, where S is a sugar moiety such as glucose, fructose, mannose, and galactose; n is from about 1 to about 1000 And R is a _C8-30 alkyl group. Examples of long-chain alcohols from which alkyl groups can be derived include decyl alcohol, cetyl alcohol, stearyl alcohol, lauryl alcohol, myristyl alcohol, oleyl alcohol, and the like. Preferred examples of such surfactants include, where S is a glucose moiety, R is a C _8-20 alkyl group, and n
Is an integer from about 1 to about 9. Examples of these commercially available surfactants include decyl polyglucoside (commercially available as APG325CS from Henkel) and lauryl polyglucoside (APG600CS and 62 from Henkel).
5CS).

Other useful nonionic surfactants include the condensation products of alkylene oxides and fatty acids (ie, alkylene oxide esters of fatty acids). These materials have the general formula RCO (X) _n OH, where R is C10-30.
Alkyl group, X is -OCH ₂ CH ₂ - (i.e., ethylene glycol or derived from oxide) or -OCH ₂ CHCH ₃ - (i.e., derived from propylene glycol or oxide), and n is from about 6 to about 200 integer is there. Other nonionic surfactants are the condensation products of alkylene oxides with two moles of fatty acids (ie, alkylene oxide diesters of fatty acids). These materials have the general formula RCO (X) _n OOCR, where R is a C _10-30 alkyl group,
It is -OCH ₂ CH ₂ - (i.e., ethylene glycol or derived from oxide) or -OCH ₂ CHCH ₃ - (i.e., derived from glycol or oxide), and n is from about 6 to about 100 integer. Another nonionic surfactant is the condensation product of an alkylene oxide with an aliphatic alcohol (ie, an alkylene oxide ether of an aliphatic alcohol). These materials have the general formula R (X) _n O
Wherein R is a C _10-30 alkyl group, X is —OCH ₂ CH ₂ — (ie, derived from ethylene glycol or oxide) or —OCH ₂ CHCH ₃ — (ie, propylene glycol or oxy ), N is an integer from about 6 to about 100, and R is H or a _C10-30 alkyl group. Still other nonionic surfactants are the condensation products of alkylene oxides with both fatty acids and aliphatic alcohols, ie, wherein the polyalkylene oxide moiety is esterified with the fatty acid at one end thereof, and Etherified with an aliphatic alcohol at the other end (ie linked via an ether bond)]. These materials have the general formula RCO (X) _n OR where R and R are C _10-30 alkyl groups;
X is -OCH ₂ CH ₂ (i.e., derived from ethylene glycol or oxide) or -OCH ₂ CHCH ₃ - (derived from propylene glycol or oxide), and n is from about 6 to about 100 integer. Examples of nonionic surfactants derived from these alkylene oxides include Ceteth-6, Ceteth-10, Ceteth-12, Ceteareth-6, Ceteareth-10, Ceteareth-12, Steareth-6, Steareth-10, Steareth-12, steareth-21, PEG-6-stearate,
PEG-10-stearate, PEG-100-stearate, PEG-12
Stearate, PEG-20-glyceryl stearate, PEG-80 glyceryl tallow, PEG-10-glyceryl stearate, PEG-30-glyceryl cocoate, PEG-80-glyceryl cocoate, PEG-200-glyceryl tallow, PEG-8-dilaurate, Including, but not limited to, PEG-10-distearate, and mixtures thereof.

Still other useful nonionic surfactants include polyhydroxy fatty acid amide surfactants corresponding to the following structural formula:

Embedded image Where: R¹Is H, C₁~ C_FourAlkyl, 2-hydroxyethyl, 2-hydroxy
-Propyl, preferably C₁~ C_FourAlkyl, more preferably methyl or ethyl,
Most preferably methyl; R^TwoIs C_Five~ C₃₁Alkyl or alkenyl, preferably C ₇ ~ C₁₉Alkyl or alkenyl, more preferably C₉~ C₁₇Alkyl or alke
Nil, most preferably C₁₁~ C_FifteenAlkyl or alkenyl; and Z is a linear hydro
Polycarbyl having a carbyl chain and at least three hydroxy groups attached directly to the chain
The hydroxyhydrocarbyl moiety, or one alkoxylated derivative thereof (preferably
Ethoxylation or propoxylation). Z is preferably glucose
, Fructose, maltose, lactose, galactose, mannose, xylo
And a sugar moiety selected from the group consisting of glucose and mixtures thereof. The above structure
A particularly preferred surfactant corresponding to is coconut alkyl N-methylglucose.
Doamide (ie, where R^TwoThe CO- moiety is derived from coconut oil fatty acids)
. Methods for producing compositions containing polyhydroxy fatty acid amides are described, for example, in the United Kingdom.
National Patent Specification No. 809,060 (Thomas Hedley &
Co., Ltd.), published February 18, 1959); U.S. Pat. No. 2,965,576.
(E.R. Wilson, issued December 20, 1960); United States
Patent No. 2,703,798 (AM Schwartz), 19
U.S. Pat. No. 1,985,424 (Piggott issued March 8, 1980).
), Issued December 25, 1934), all of which are referenced.
And incorporated herein by reference.

Among the nonionic surfactants, preferred are steareth-21, ceteares-
20, ceteareth-12, sucrose cocoate, steareth-100, PEG
A nonionic surfactant selected from the group consisting of -100-stearate, and mixtures thereof.

Other nonionic surfactants suitable for use in the present invention include sugar esters and polyesters, alkoxylated sugar esters and polyesters, C ₁ -C ₃₀ fatty acid esters of C ₁ -C ₃₀ fatty alcohols. , C ₁ -C ₃₀ alkoxylated derivatives of C ₁ -C _{3 0} fatty acid esters of fatty alcohols, C ₁ -C ₃₀ alkoxylated ethers of aliphatic alcohols, polyglyceryl esters of C ₁ -C ₃₀ fatty acid, a polyol C1~ of C30 esters, C ₁ -C ₃₀ ethers of polyols, alkyl phosphates, polyoxyalkylene fatty ether phosphates, fatty acid amides, acyl lactylates, and mixtures thereof. Examples of these emulsifiers include polyethylene glycol-20-sorbitan monolaurate (Polysorbate).
orbate) -20), polyethylene glycol-5-soy sterol, steareth-20, ceteareth-20, polypropylene glycol-2-methylglucose ether distearate, ceteth-10, polysorbate-80, cetyl phosphate, potassium cetyl phosphate, diethanolamine Cetyl phosphate, polysorbate-60, glyceryl stearate, polyoxyethylene-20-sorbitan trioleate (polysorbate-85), sorbitan monolaurate,
Polyoxyethylene-4-lauryl ether sodium stearate, polyglyceryl-4-isostearate, hexyl laurate, polypropylene glycol-2-methylglucose ether distearate, PEG-100-stearate, and mixtures thereof. However, it is not limited to these.

Another group of nonionic surfactants useful herein includes fatty acid ester mixtures based on sorbitan or a mixture of sorbitol fatty acid esters and sucrose fatty acid esters, wherein the fatty acids are in each case also preferably C ₈ ~C _{2 4,} more preferably from C ₁₀ -C _20. Preferred fatty acid ester emulsifier is a sorbitan or sorbitol C ₁₆ -C ₂₀ fatty acid esters, sucrose C ₁₀ -C ₁₆ fatty acid esters, especially mixtures of sorbitan stearate and sucrose cocoate. It is commercially available from ICI under the trade name Arlatone 2121.

Other suitable surfactants useful herein include a wide variety of cationic, anionic, zwitterionic, and amphoteric surfactants well known in the art and described in detail below. Agent included. For example, McCutcheon's “Detergents and Emulsifiers”
US Pat. No. 5,011,681 (Ciotti et al., issued on Apr. 30, 1991); U.S. Pat. No. 4,421, No. 769 (Dixon et al., Issued Dec. 20, 1983) and US Pat. No. 3,755,560 (Dickert et al., Issued Aug. 28, 1973) are all references. And incorporated herein by reference. Hydrophilic surfactants useful herein can include a single surfactant, or any combination of suitable surfactants. Whether a suitable surfactant (or surfactants) is selected depends on the pH of the composition and other components present.

Further cationic surfactants useful in the present invention include dialkyl quaternary ammonium compounds, examples of which include US Pat. No. 5,151,209; US Pat. No. 210; U.S. Pat. No. 5,120,532; U.S. Pat.
87,090; U.S. Pat. No. 3,155,591; U.S. Pat. No. 3,929,6.
No. 78; US Pat. No. 3,959,461; Makkachan's "Detergents and Emulsifiers"
(North America, 1979); C. Publishing Company; and Schwartz et al., "Surfactants, Their Science and Technology" (Surface Active
Agents, Their Chemistry and Technology), New York: Interscience Publishers, 1949; incorporated herein by reference. Cationic surfactants useful herein further include cationic ammonium salts having the formula:

Embedded image Wherein R ₁ is an alkyl group having about 12 to about 30 carbon atoms, or an aromatic, aryl or alkaryl group having about 12 to about 30 carbon atoms; R ₂ , R ₃ , and R ₄ is each independently selected from hydrogen, an alkyl group having about 1 to about 22 carbon atoms, or an aromatic, aryl or alkaryl group having about 12 to about 22 carbon atoms; and X is Any compatible anion, preferably chloride, bromide, iodide, acetate, phosphate, nitrate, sulfate, methyl sulfate, ethyl sulfate, tosylate, lactate, citrate, glycolate, and mixtures thereof More choice. Furthermore, R ₁
, R ₂ , R ₃ , and R ₄ further comprise an ester and / or ether linkage;
Alternatively, it may contain a hydroxy or amino substituent (eg, the alkyl group may contain polyethylene glycol and polypropylene glycol moieties).

More preferably, R ₁ is an alkyl group having about 12 to about 22 carbon atoms; R ₂ is selected from hydrogen or an alkyl group having about 1 to about 22 carbon atoms; R ₃ and R ₄ each are independently selected from hydrogen or an alkyl group having from about 1 to about 3 carbon atoms; and X are as described above.

Even more preferably, R ₁ is an alkyl group having about 12 to about 22 carbon atoms; R ₂ , R ₃ , and R ₄ are H or about 1 to about 3 carbon atoms. And X is as described above.

Alternatively, other effective cationic emulsifiers include amino-amides, wherein R ₁ in the above structure is alternatively R ₅ CONH- (CH ₂ ) _n
Wherein R ₅ is an alkyl group having about 12 to about 22 carbon atoms and n is about 2
An integer from about 2 to about 6, more preferably from about 2 to about 4, and even more preferably from about 2 to about 3. Examples of these cationic emulsifiers include stearoamidopropyl PG-dimonium chloride phosphate, behenamidopropyl PG dimonium chloride, stearoamidopropylethyldimonium ethosulfate, stearoamidopropyl dimethyl (myristyl acetate) chloride. Ammonium, stearoamidopropyl dimethyl cetearyl ammonium tosylate, stearoamidopropyl dimethyl ammonium chloride, stearoamidopropyl dimethyl ammonium lactate, and mixtures thereof. Particularly preferred is behenamidopropyl PG dimonium chloride.

Examples of quaternary ammonium salt cationic surfactants include cetyl ammonium chloride, cetyl ammonium bromide, lauryl ammonium chloride, ammonium lauryl bromide, stearyl ammonium chloride, stearyl ammonium bromide, cetyl dimethyl ammonium chloride , Cetyl dimethyl ammonium bromide, lauryl dimethyl ammonium chloride, lauryl dimethyl ammonium bromide, stearyl dimethyl ammonium chloride, stearyl dimethyl ammonium bromide, cetyl trimethyl ammonium chloride, cetyl trimethyl ammonium bromide, lauryl trimethyl ammonium chloride, lauryl trimethyl ammonium bromide , Stearyl trimethyl ammonium chloride, stearyl trimethyl ammonium bromide, lauryl dimethyl ammonium chloride , Stearyl dimethyl cetyl ditallow dimethyl ammonium chloride,
Dicetyl ammonium chloride, dicetyl ammonium bromide, dilauryl ammonium chloride, dilauryl ammonium bromide, distearyl ammonium chloride, distearyl ammonium bromide, dicetyl methyl ammonium chloride, dicetyl methyl ammonium bromide, dilauryl methyl ammonium chloride, dilauryl methyl ammonium bromide , Distearyl methyl ammonium chloride, distearyl methyl ammonium bromide, and mixtures thereof, but is not limited thereto. Further, quaternary ammonium salts include those in which the C ₁₂ to C ₃₀ alkyl carbon chain is derived from tallow fatty acids or coconut fatty acids. The term "tallow" refers generally to the C _16, such as have mixtures of alkyl chains in the range of C _18, alkyl group derived from tallow fatty acids (usually hydrogenated tallow fatty acids). "
The term coconut "generally as have mixtures of alkyl chains in the range of C ₁₂ to C _14, it refers to an alkyl group derived from a coconut fatty acid. Examples of quaternary ammonium salts derived from tallow or coconut include ditallow dimethyl ammonium chloride, ditallow dimethyl ammonium methyl sulfate, di (hydrogenated tallow) dimethyl ammonium chloride, di (hydrogenated tallow) dimethyl ammonium acetate Ammonium ditallow dipropyl phosphate, ditallow dimethyl ammonium nitrate, di (coconut alkyl) dimethyl ammonium chloride, di (coconut alkyl) dimethyl ammonium bromide, tallow ammonium chloride, coconut ammonium chloride, stearoamidopropyl PG-dimonium chloride , Stearoamidopropylethyldimonium esosulfate, stearoamidopropyldimethyl (myristyl acetate) ammonium chloride, stearoamidopropion Dimethyl cetearyl ammonium tosylate, stearamide dimethyl ammonium chloride, stearamidopropyl dimethylamine lactate ammonium, and mixtures thereof. An example of a quaternary ammonium compound having an alkyl group with an ester linkage is ditallowyloxyethyl dimethyl ammonium chloride.

Further preferred cationic surfactants are behenamidopropyl PG dimonium chloride, dilauryl dimethyl ammonium chloride, distearyl dimethyl ammonium chloride, dimyristyl dimethyl ammonium chloride, dipalmityl dimethyl ammonium chloride, distearyl dimethyl chloride. Ammonium, stearoamidopropyl PG dimonium chloride, stearoamidopropyl ethyl diammonium esulfate, stearoamidopropyl dimethyl (myristyl acetate)
It is selected from the group consisting of ammonium chloride, stearoamidopropyl dimethyl cetearyl ammonium tosylate, stearoamidopropyl dimethyl ammonium chloride, stearoamidopropyl dimethyl ammonium lactate, and mixtures thereof.

Still more preferred cationic surfactants are behenamide propyl PG dimonium chloride, dimonium chloride, dilauryl dimethyl ammonium chloride, distearyl dimethyl ammonium chloride, dimyristyl dimethyl ammonium chloride, dipalmityl dimethyl ammonium chloride And mixtures thereof.

A preferred combination of a cationic surfactant and a constituent is behenamidopropyl PG dimonium chloride and / or behenyl alcohol, especially when such a combination contains a highly ionic and / or polar solvent. It is preferable to optimize the ratio so as to increase the physical and chemical stability. This combination is particularly useful for use in sunscreens such as zinc oxide and octyl methoxycinnamic acid.

A wide variety of anionic surfactants are further useful in the present invention. All of which are cited by reference and all of which are incorporated herein, e.g.,
U.S. Pat. No. 3,929,678 issued Dec. 30, 1975.
checking ... Examples of anionic surfactants include, but are not limited to, alcohol isethionate, and alkyl and alkyl ether sulfates. Arco isethionate salt generally has a formula _{RCO-OCH 2 CH 2 SO 3} M, in in this formula, R is an alkyl or alkenyl group having from about 10 to about 30 carbon atoms, M Are water-soluble cations such as ammonium, sodium, potassium, and triethanolamine. Examples of isethionates include those cocoyl isethionates selected from ammonium coconut oil isethionate, sodium coconut oil isethionate, sodium lauroylisethionate, sodium stearoyl isethionate, and mixtures thereof. However, it is not limited to these.

Alkyl and alkyl ether sulfates are generally of the formula ROSO ₃
Has a M and _{RO (C 2 H 4 O)} x SO 3 M, wherein, R is an alkyl or alkenyl group having from about 10 to about 30 carbon atoms, x is from about 1 to about 10, M Are water-soluble cations such as ammonium, sodium, potassium, and triethanolamine. Another suitable class of anionic surfactants having the following general formula, organic, are water-soluble salts of sulfuric acid reaction products: R in ₁ -SO ₃ -M formula, R ₁ is a straight-chain or About 8 to about 24, preferably about 10 to about 16,
Is selected from the group comprising saturated aliphatic hydrocarbon groups having three carbon atoms; M is a cation. Still other anionic synthetic surfactants include succinamic acid salts,
Includes olefin sulfonates having from about 12 to about 24 carbon atoms, and the class designated as β-alkyloxyalkane sulfonates. Examples of such materials are sodium lauryl sulfate and ammonium lauryl sulfate.

Other anionic materials useful herein are soaps of fatty acids (ie, alkali metal salts, such as, for example, sodium or potassium salts) and generally have from about 8 to about 24 carbon atoms. And preferably has about 10 to about 20 carbon atoms. Fatty acids used to make soap are natural resources, such as glycerides of plant or animal origin (eg, palm oil, coconut oil, soybean oil, castor oil, tallow, lard, etc.).
Can be obtained from Fatty acids can be further prepared synthetically. Soaps are further described in U.S. Pat. No. 4,557,853.

Amphoteric and zwitterionic surfactants are further effective in the present invention. Examples of amphoteric and zwitterionic surfactants that can be used in the compositions of the present invention include those wherein the aliphatic group can be straight or branched and one of the aliphatic substituents has from about 8 to about 22 carbon atoms. (Preferably C _8-
C18 and one are widely described as derivatives of aliphatic secondary and tertiary amines containing a water-soluble group of anions, such as carboxy, sulfonate, sulfate, phosphate, or phosphonate. As an example, the formula RN [CH ₂ ) _m CO ₂
M] ₂ and RNH (CH _{2) m} CO ₂ alkyl imino acetates, such as M, and there is iminodialkanoates acids and amino alkanoate such, the m is there 1
From 4, R is an alkyl or alkenyl group C ₈ -C _22, M is hydrogen, alkali metal, alkaline earth metal ammonium or alkanolammonium,. Further included are imidazolinium and ammonium derivatives. Specific examples of suitable amphoteric surfactants include sodium 3-dodecyl-aminopropionate,
Sodium 3-dodecylaminopropanesulfonate, such as that formed by reacting dodecylamine with sodium isethionate as described in U.S. Pat. No. 2,658,072, which is incorporated by reference in its entirety. N-alkyl taurines; N-higher alkyl aspartic acids such as those produced as described in U.S. Pat. No. 2,438,091 which is incorporated by reference herein in its entirety; "Miranol" ), Which are described in U.S. Pat. No. 2,528,378, which is incorporated by reference herein in its entirety. Other examples of useful zwitterions include phosphates such as coamidopropyl PG-dimonium chloride phosphate (commercially available from Monacorp as Monaquat PTC).

Other amphoteric or zwitterionic surfactants useful herein include betaine. Examples of betaines include, for example, cocodimethylcarboxymethylbetaine, lauryldimethylcarboxymethylbetaine, lauryldimethylalphacarboxyethylbetaine, cetyldimethylcarboxymethylbetaine, cetyldimethylbetaine (commercially available under the name Lonzaine 16SP from Lonza). Lauryl bis- (2-hydroxyethyl) carboxymethyl betaine, stearyl bis- (2-hydroxypropyl) carboxymethyl betaine, oleyldimethyl gamma-carboxypropyl betaine, lauryl bis- (2-hydroxypropyl) alpha-carboxyethyl betaine , Cocodimethylsulfopropylbetaine, stearyldimethylsulfopropylbetaine, lauryldimethylsulfoethylbetaine, laurylbi Scan - (2-hydroxyethyl) sulfopropyl betaine, and higher alkali betaines and amido sulfobetaines, such as betaines (this time RCONH (CH _{2) 3} group is attached to the nitrogen atom of the betaine.
), Oleyl betaine (commercially available from Henkel as amphoteric Vervetec OLB-50) and cocamidopropyl betaine (commercially available from Henkel as Vervetex BK-35 and BA-35).

Other useful amphoteric and zwitterionic surfactants include sultaines and hydroxysultaines such as cocamidopropylhydroxysultaine (commercially available from Rhone-Poulenc as miratein CBS) and the formula RCON (CH ₃ ) CH ₂ CH ₂ CO ₂ M
Wherein R is an alkyl or alkenyl group having about 10 to about 20 carbon atoms, and M is an ammonium, sodium, potassium and trialkanolamine (eg, triethanolamine). Such a water-soluble cation, preferred among the examples, is sodium lauroyl sarcosinate.

(3) Water Preferred oil-in-water emulsions comprise from about 25 to about 98% by weight of the topical carrier.
Preferably it contains about 65 to about 95% by weight, more preferably about 70 to about 90% by weight of water.

The hydrophobic phase is dispersed in a continuous aqueous phase. The hydrophobic phase can be any water-insoluble or partially water-soluble or partially oil known to those skilled in the art, including but not limited to the silicones described herein for the silicone-in-water emulsions and other oils and lipids as described above for the emulsions. May contain soluble material.

The topical compositions of the present invention may contain a dermatologically acceptable emollient, including but not limited to lotions and creams. Such compositions preferably contain from about 1% to about 50% of an emollient. "Emollient" as used in the present invention refers to a substance that is effective in protecting the skin as well as preventing and reducing drying. A wide variety of suitable emollients are known and can be used in the present invention. Sagarin 「Cosmetics, Science an
d Technology) Second Edition, Vol. 1, pp. 32-43 (1972), which contains a number of examples of materials suitable as emollients and are incorporated herein by reference. A preferred emollient is glycerin. Glycerin is preferably from about 0.001 to about 30
%, More preferably from about 0.01 to about 20%, even more preferably from about 0.1 to about 1%.
It is used in an amount of 0%, for example 5%.

The lotions and creams according to the invention generally contain a solution carrier system and one or more emollients. Lotions and creams typically contain about 1 to about 50%, preferably about 1 to about 20%, of an emollient; about 50 to about 90%,
It preferably contains about 60 to about 80% water; and the above-mentioned amounts of farnesol, bisabolol, and additional skin care actives. Creams are usually thicker than lotions because of the high concentration of emollients or thickening agents.

The ointments of the invention may be simple carrier bases (oil-based) of animal or vegetable oils or semi-solid hydrocarbons; ointment bases for absorption which absorb water to form emulsions; or water-soluble carriers such as aqueous solutions May be contained. Ointments are further described by Sagarin, Cosme Science and Technology (Cosme), which is incorporated herein by reference.
tics, Science and Technology), 2nd edition, Volume 1, pages 72-73 (1972)
, And / or emollients. For example,
The ointment may contain from about 2 to about 10% of an emollient; from about 0.1 to about 2% of a thickener component; and the above amounts of farnesol, bisabolol, and the additional skin care active.

Compositions of the invention useful for washing ("cleaning agents") are formulated, for example, with a suitable carrier as described above, and preferably in the abovementioned amounts of farnesol, bisabolol,
And, in addition to the additional skin care active, preferably contains about 1 to about 90%, more preferably about 5 to about 10% of a dermatologically acceptable surfactant. Suitable surfactants are selected from anionic, non-ionic, zwitterionic, zwitterionic and amphoteric surfactants and mixtures of such surfactants. Such surfactants are well known to those skilled in the detergent art. Non-limiting examples of potential surfactants include Isoceteth-20, sodium methyl cocoyl taurate, sodium methyl oleoyl taurate, and sodium lauryl sulfate. For examples of surfactants useful in the present invention, see US Pat. No. 4,800,197 (Kotz), which is hereby incorporated by reference in its entirety.
wcz) et al., issued January 24, 1989). Examples of a wide variety of additional surfactants useful herein are McCutchen's "Cleaners and Emulsifiers" (McCutche
on's Detergents and Emulsifiers), North American version (1986), published by Allured Publishing Corporation. The detergent composition may optionally contain other substances conventionally used in detergent compositions at art-established concentrations.

[0136] The physical form of the detergent composition is not critical. The composition can be formulated, for example, as a facial cleanser, liquid, shampoo, bath gel, hair conditioner, hair tonic, paste, or mousse. Rinse-off detergent compositions, such as shampoos, require a suitable delivery system to deposit a sufficient concentration of active on the skin and scalp. A preferred delivery system involves the use of an insoluble complex.
A more complete disclosure of such a delivery system is found in U.S. Pat.
No. 5,148 (Barford et al., Issued May 30, 1989).

The term “foundation” as used herein, includes, but is not limited to, liquid, semi-liquid, semi-solid, or solid skin, including lotions, creams, gels, pastes, solid foundations, and the like. Means cosmetics. Generally, foundations are used on large areas of skin, such as on the face, to achieve a particular look. Foundations generally provide an adherent base for colored cosmetics such as lipsticks, blushers, powders, etc., tend to mask skin imperfections and give the skin a smooth, flat appearance. The foundation of the present invention comprises a dermatologically acceptable carrier and may contain commonly used components such as oils, colorants, pigments, emollients, perfumes, waxes, stabilizers and the like. Suitable for use in the present invention,
Representative carriers and such other components are described, for example, in PCT Application WO96
No./33689 (Canter et al., Issued Oct. 31, 1996) and British Patent GB 2274585 (issued Aug. 3, 1994).

Preparation of Compositions Compositions useful in the method of the present invention are usually prepared by conventional methods known in the art as methods of preparing topical compositions. Such methods typically include mixing the components in one or more steps to a relatively uniform state with or without heating, cooling, applying vacuum, or the like. .

Method for Regulating Skin Condition The composition of the present invention is effective for regulating the condition of mammalian skin. Such adjustments to keratinous tissue status include prophylactic and therapeutic adjustments. For example, such adjustment methods include thickening of keratinous tissue (i.e., formation of the epidermal and / or dermal layers of the skin to which the keratinous layers of the nail and hair shaft are applicable) and prevention of atrophy of the mammalian skin and / or Or delay, prevention and / or delay of the appearance of spider vessels and / or red spots on the skin of a mammal, prevention and / or delay of the appearance of dark spots under the eyes of a mammal, poor bloodiness of the skin of a mammal Prevention and / or delay, prevention and / or delay of sagging of mammalian skin, softening and / or smoothing of lips, hair and nails of mammal, prevention and / or removal of itching of mammalian skin , For adjusting skin texture (eg, wrinkles and fine lines) and improving skin color (eg, redness, freckles).

Modulating the condition of keratinous tissue involves topical application of a composition of the present invention to a safe and effective amount of keratinous tissue. The amount of composition applied, frequency of application, and duration of use will depend on the concentration of farnesol, bisabolol, and additional skin care actives and / or other components or actives in the given composition, and the degree of adjustment desired. It varies widely, for example, taking into account the degree of keratinous tissue damage present or expected to occur.

In a preferred embodiment, the compositions of the invention are applied to the skin for an extended period of time. "Long-term topical application" refers to prolonged life of the subject, preferably for at least about 1 week, more preferably for at least about 1 month, even more preferably for at least about 3 months, even more preferably for at least about 6 months. It means continuous topical application of the composition of the present invention for a period of months, and even more preferably for at least about one year. The effect can be obtained after various maximum periods of use (e.g., 5, 10 or 20 years), but it is preferred to continue the application for a long period of time throughout the life of the subject. Typically, over time, application will be on the order of about once per day, but the frequency of application can vary from about once per week to about 3 times per day or more.

The compositions of the present invention can be used in a wide range of amounts to provide skin appearance and / or feel benefits. The amount of the composition of the invention typically applied per application is from about 0.1 mg / cm ² to about 10 mg / cm ^{2 in} mg of composition / cm ² of skin. Particularly useful application amount is about 1 mg / cm ² ~ about 2 mg / cm ^2.

Adjustment of the condition of the keratinous tissue is preferably a skin lotion, cream, gel, foam, ointment, intended to remain on the skin or other keratinous structure for aesthetic, prophylactic, therapeutic or any other effect. It is preferably carried out by applying a composition in the form of a paste, emulsion, spray, conditioner, tonic, cosmetic, lipstick, foundation, nail enamel, aftershave lotion, etc. (ie a "leave-on" composition). After application of the composition to the skin, the composition is preferably at least about 15 minutes, more preferably at least about 30 minutes, even more preferably at least about 1 hour, even more preferably at least several hours, such as up to about 12 hours. Is left on the skin for a while. face,
Any part of the hair and / or outside the nails, such as the face, lips, areas under the eyes,
Eyelids, scalp, neck, trunk, arms, hands, legs, feet, fingernails, toenails, hair, eyelashes,
It can treat eyebrows and the like. The composition can be a finger or an instrument or device (eg, a pad,
Swabs, applicator pens, spray applicators, etc.).

Another method of ensuring continuous exposure of the skin to at least the lowest concentrations of the farnesol, bisabolol, and additional skin care actives is to use the patch to apply the compound, eg, to the face To apply. Such a method is particularly effective for skin area problems that require thorough treatment (e.g., facial crow's feet (wrinkles of the eyes), wrinkle lines between the eyebrows, areas under the eyes, etc.). The patch may be occlusive, semi-occlusive or non-occlusive, and adhesive or non-adhesive.
The compositions and actives of the present invention can be contained within a patch or applied to the skin before applying the patch. The patch is further disclosed in U.S. Pat.
No. 250, US Pat. No. 5,981,547, and US Pat. No. 5,972,955.
No. 7 (Wu et al.), Such as a chemical initiator for the exothermic reaction,
It may contain additional active substances. The patch is preferably on the skin for at least about 5 minutes, more preferably at least about 15 minutes, more preferably at least about 30 minutes, even more preferably at least about 1 hour, even more preferably at night in the form of night therapy. , Leave it stuck.

[0145]

【Example】

The following examples further describe and illustrate examples within the scope of the invention. These examples are provided for illustrative purposes only, and numerous modifications of the present invention are possible without departing from the spirit and scope of the present invention and are not intended to limit the present invention.

Examples 1-6 A skin cream is prepared from the following ingredients by a conventional method.

[Table 1] ^One peptide was Matrixyl (100 ppm of palmitoyl-Lys-
Commercially available as Thr-Thr-Lys-Ser from Sederma ^* Commercially available from KOBO.

Mix the A-phase components with a suitable mixer (eg, Tekmer model RW20DZM)
And heat with stirring to a temperature of 70-80 ° C. Separately, the Phase B components are mixed in a suitable mixer, heated to 70-75 ° C., and the temperature is maintained while stirring. Add phase B to phase A with sufficient stirring and emulsify. When the emulsion is at about 60 ° C., add phase C while stirring and mix the emulsion.
Cool the emulsion to about 40 ° C while stirring. At about 50 ° C, D
Add phase and phase E to the emulsion and continue mixing. At about 40 ° C., add phase F and phase G to the emulsion. The emulsion is then milled for about 5 minutes using a suitable mill (Tecmer T25) to obtain a uniform product.

Examples 7-10 Skin lotions are prepared by conventional methods from the following ingredients.

[Table 2] ^One peptide was Matrixyl (100 ppm of palmitoyl-Lys-
Commercially available from (Sederma) as Thr-Thr-Lys-Ser ^* Commercially available from US Cosmetics.

Mix phase A components with a suitable mixer (eg, Model RW20DZM from Techmer)
And heat with stirring to a temperature of 70-80 ° C. Separately, the Phase B components are mixed in a suitable mixer, heated to 70-75 ° C., and the temperature is maintained while stirring. Add phase B to phase A with sufficient stirring and emulsify. When the emulsion is at about 60 ° C., add phase C while stirring and mix the emulsion.
Cool the emulsion to about 40 ° C while stirring. At about 50 ° C, D
Add the phase to the emulsion and continue mixing. At about 40 ° C., add phase E and phase F to the emulsion. This emulsion is then used in a suitable mill (Tecmer T2)
Knead for about 5 minutes using 5) to obtain a uniform product.

Examples 12-17 A skin cream is prepared from the following ingredients by a conventional method.

[Table 3] ^One peptide was Matrixyl (100 ppm of palmitoyl-Lys-
Commercially available as Thr-Thr-Lys-Ser from Sederma ^* Commercially available from KOBO.

Mix the Phase A constituents in a suitable mixer (eg, Tekmer model RW20DZM)
And heat with stirring to a temperature of 70-80 ° C. Separately, the Phase B components are mixed in a suitable mixer, heated to 70-75 ° C., and the temperature is maintained while stirring. Add phase B to phase A with sufficient stirring and emulsify. When the emulsion is at about 60 ° C., add phase C while stirring and mix the emulsion.
Cool the emulsion to about 40 ° C while stirring. At about 50 ° C, D
Add phase and phase E to the emulsion and continue mixing. At about 40 ° C., add the F, G, and H phases to the emulsion. The emulsion is then milled for about 5 minutes using a suitable mill (Tecmer T25) to obtain a uniform product.

[Sequence list]

──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. ⁷ Identification symbol FI Theme coat ゛ (Reference) A61K 31/045 A61K 31/045 31/07 31/07 31/12 31/12 31/164 31/164 31 / 216 31/216 31/255 31/255 31/28 31/28 31/353 31/353 31/355 31/355 31/4406 31/4406 31/618 31/618 38/00 A61P 17/10 A61P 17 / 10 17/16 17/16 29/00 29/00 31/04 31/04 31/10 31/10 43/00 111 43/00 111 A61K 37/02 (31) Priority number 60 / 175,315 (32) Priority date January 10, 2000 (Jan. 10, 2000) (33) Priority claiming country United States (US) (31) Priority claim number 09 / 541,965 (32) Priority date 2000 April 4 (2000.4.4) (33) Priority claim country United States (US) (31) Priority claim number 09 / 544,783 (32) Priority date April 7, 2000 (2000.4) .7) (33) Priority (81) Designated country EP (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE) , OA (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG), AP (GH, GM, KE, LS, MW, SD, SL) , SZ, TZ, UG, ZW), EA (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR , BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, M , MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW (72) Inventor Robinson, Larry Richard, Ohio, USA, Loveland, Tumbleweed, Drive 1114 (72) Inventor Bissett, Donald Lyn, Ohio, United States of America, Hamilton, Dust, Commander, Drive 3925 (72) Inventor Deckner, George Ender Cincinnati, Tanjaja, Hills, Drive, Ohio, USA 10572 (72) Inventor Ha, Robert Bao Kim, Ohio, United States, Milford, Mary, Avenue 1199 F-term (reference) 4C083 AB211 AB241 AB242 AC072 AC091 AC092 AC122 AC152 AC172 AC182 AC211 AC341 AC342 AC44 2 AC472 AC482 AC532 AC641 AC642 AC682 AC791 AC792 AC841 AC851 AC852 AD152 AD411 AD412 AD532 AD621 AD622 AD631 AD661 AD662 CC02 CC05 DD31 EE12 EE13 4C084 AA02 AA03 BA01 BA08 BA14 BA15 BA16 CA62 DC50 MA02 MA63 NA13 ZA292 ZB92 A112 ZA292 ZA92B112A01 DA17 HA06 HA21 MA01 MA02 MA03 MA04 MA08 MA10 MA28 MA63 NA13 ZA29 ZA89 ZB11 ZB35 ZC02 4C206 AA01 AA02 CA05 CA07 CA08 CA09 CB19 DB20 DB43 GA26 JA06 MA01 MA02 MA03 MA04 MA11 MA12 MA30 MA48 MA83 NA13 ZA29 ZA35 ZB11Z

Claims (10)

[Claims] 1. A skin care composition comprising: a) a safe and effective amount, preferably from 0.1 to 10% by weight of the composition, of farnesol; b) a safe and effective amount, preferably of the composition. A skin care composition comprising 0.1-10% by weight of bisabolol; c) a safe and effective amount of at least one additional skin care active; and d) a dermatologically acceptable carrier. Wherein said additional skin care active, peeling actives, anti-acne actives, vitamin B ₃ compounds, retinoids, peptides, hydroxy acids, antioxidants, radical scavengers, chelating agents, anti-inflammatory agents, topical Anesthetics, sunburn actives, skin lightening agents, anti-cellulite agents, flavonoids, antibacterial actives, skin smoothing agents, skin healing agents, antifungal actives, sunscreen actives, conditioning agents, constituents, thickeners, and 2. The composition of claim 1, wherein the composition is selected from the group consisting of mixtures thereof.
3. The skin care composition according to item 1. 3. The skin care composition according to claim 1, wherein the additional skin care active is phytantriol. 4. The method according to claim 1, wherein the additional skin care active is selected from the group consisting of vitamin B ₃ compounds, and mixtures thereof, preferably the additional skin care active is nicotinamide. A skin care composition as described. 5. The skin care composition according to claim 1, wherein the additional skin care active is salicylic acid. 6. The method of claim 1, wherein the additional skin care active is Lys-Thr-Thr-.
Lys-Ser, Gly-His-Lys, β-Ala-His, Arg-Se
a peptide active substance selected from the group consisting of r-Arg-Lys, Arg-Lys-Arg, His-Gly-Gly, derivatives thereof, and mixtures thereof, preferably wherein the peptide active substance is palmitoyl-Lys -Thr-T
The skin care composition according to claim 1, 3, 4, or 5, which is hr-Lys-Ser. 7. The skin care composition according to claim 1, wherein the additional skin care active is a mixture of nicotinamide, tocopherol acetate, and dexpanthenol. 8. The additional skin care active comprises titanium dioxide having an average primary particle size of about 15 to about 100 nm, and an average primary particle size of about 15 to about 150.
selected from the group consisting of zinc oxide having an average particle size of about 15 nm, zirconium oxide having an average particle size of about 15 to about 150 nm, iron oxide having an average particle size of about 15 to about 500 nm, and mixtures thereof. The skin care composition according to claim 1 or 2, which is an inorganic sunscreen containing a metal oxide. 9. An organic sunscreen wherein the additional skin care active is selected from the group consisting of octyl methoxy cinnamate, octyl salicylate, terephthalidene dicamphor sulfonic acid, avobenzone, octocrylene, and mixtures thereof. The skin care composition according to claim 1 or 2, which is an agent. 10. A method as claimed in any one of the preceding claims for the manufacture of a medicament for regulating the condition of mammalian skin by topical application to the skin of the mammal in need of treatment. Use of skin care compositions.